

# Patrick W Serruys

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7006341/publications.pdf>

Version: 2024-02-01

775  
papers

79,339  
citations

870

117  
h-index

549

264  
g-index

850  
all docs

850  
docs citations

850  
times ranked

27136  
citing authors

#	ARTICLE	IF	CITATIONS
1	PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 28-38.	1.4	39
2	Long-term survival after coronary bypass surgery with multiple versus single arterial grafts. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 61, 925-933.	0.6	19
3	Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with <i>de novo</i> three-vessel disease: final results of the SYNTAX II study. <i>European Heart Journal</i> , 2022, 43, 1307-1316.	1.0	54
4	End-diastolic segmentation of intravascular ultrasound images enables more reproducible volumetric analysis of atheroma burden. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 706-713.	0.7	3
5	Single or multiple arterial bypass graft surgery vs. percutaneous coronary intervention in patients with three-vessel or left main coronary artery disease. <i>European Heart Journal</i> , 2022, 43, 1334-1344.	1.0	17
6	Successful Coronary Artery Bypass Grafting Based Solely on Non-Invasive Coronary Computed Tomography Angiography. <i>Cardiovascular Revascularization Medicine</i> , 2022, 40, 187-189.	0.3	4
7	Impact of coronary calcification assessed by coronary CT angiography on treatment decision in patients with three-vessel CAD: insights from SYNTAX III trial. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2022, 34, 176-184.	0.5	5
8	Recovery of platelet reactivity following cessation of either aspirin or ticagrelor in patients treated with dual antiplatelet therapy following percutaneous coronary intervention: a GLOBAL LEADERS substudy. <i>Platelets</i> , 2022, 33, 141-146.	1.1	7
9	Ten-year all-cause mortality according to smoking status in patients with severe coronary artery disease undergoing surgical or percutaneous revascularization. <i>European Journal of Preventive Cardiology</i> , 2022, 29, 312-320.	0.8	6
10	One-year performance of biorestorative polymeric coronary bypass grafts in an ovine model: correlation between early biomechanics and late serial Quantitative Flow Ratio. <i>European Journal of Cardio-thoracic Surgery</i> , 2022, 61, 1402-1411.	0.6	3
11	Safety and Efficacy of Myval Implantation in Patients with Severe Bicuspid Aortic Valve Stenosis—A Multicenter Real-World Experience. <i>Journal of Clinical Medicine</i> , 2022, 11, 443.	1.0	14
12	10-Year All-Cause Mortality Following Percutaneous or Surgical Revascularization in Patients With Heavy Calcification. <i>JACC: Cardiovascular Interventions</i> , 2022, 15, 193-204.	1.1	23
13	Geographical variations in left main coronary artery revascularisation: a prespecified analysis of the EXCEL trial. <i>EuroIntervention</i> , 2022, 17, 1081-1090.	1.4	2
14	<i>EuroIntervention</i> : the 200th issue. <i>EuroIntervention</i> , 2022, 17, 1041-1043.	1.4	0
15	CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022. <i>Cardiovascular Intervention and Therapeutics</i> , 2022, 37, 1-34.	1.2	62
16	Machine learning for atherosclerotic tissue component classification in combined near-infrared spectroscopy intravascular ultrasound imaging: Validation against histology. <i>Atherosclerosis</i> , 2022, 345, 15-25.	0.4	4
17	Myval versus alternative balloon- and self-expandable transcatheter heart valves: A central core lab analysis of conduction disturbances. <i>International Journal of Cardiology</i> , 2022, 351, 25-31.	0.8	15
18	Survival or survivors?. <i>European Heart Journal</i> , 2022, , .	1.0	0

#	ARTICLE	IF	CITATIONS
19	Reply: Composite endpoints in clinical trials - simplicity or perfection?. <i>EuroIntervention</i> , 2022, 17, 1121-1122.	1.4	2
20	Healed Coronary Plaque Assessed by Light-Based Intracoronary Imaging Techniquesâ€”â€• The Good, the Bad, and the Ugly? â€•. <i>Circulation Journal</i> , 2022, 86, 855-856.	0.7	2
21	Angiography-derived physiology guidance vs usual care in an All-comers PCI population treated with the healing-targeted supreme stent and Ticagrelor monotherapy: PIONEER IV trial design. <i>American Heart Journal</i> , 2022, 246, 32-43.	1.2	1
22	Acute and chronic exercise training in patients with Class II pulmonary hypertension: effects on haemodynamics and symptoms. <i>ESC Heart Failure</i> , 2022, , .	1.4	1
23	Diagnostic concordance and discordance between angiography-based quantitative flow ratio and fractional flow reserve derived from computed tomography in complex coronary artery disease. <i>Journal of Cardiovascular Computed Tomography</i> , 2022, 16, 336-342.	0.7	5
24	A systematic review and meta-analysis of percutaneous coronary intervention compared to coronary artery bypass grafting in non-ST-elevation acute coronary syndrome. <i>Scientific Reports</i> , 2022, 12, 5138.	1.6	6
25	Ticagrelor Monotherapy or Dual Antiplatelet Therapy After Drugâ€•Eluting Stent Implantation: Perâ€•Protocol Analysis of the GLOBAL LEADERS Trial. <i>Journal of the American Heart Association</i> , 2022, 11, e024291.	1.6	4
26	A comparison of risk prediction models for patients with acute coronary syndromes. <i>EuroIntervention</i> , 2022, 17, 1362-1364.	1.4	0
27	An automated software for real-time quantification of wall shear stress distribution in quantitative coronary angiography data. <i>International Journal of Cardiology</i> , 2022, , .	0.8	4
28	Contextualizing National Policies Regulating Access to Lowâ€•Dose Aspirin in America and Europe Using the Full Report of a Transatlantic Patient Survey of Aspirin in Preventive Cardiology. <i>Journal of the American Heart Association</i> , 2022, 11, e023995.	1.6	2
29	Non-Newtonian Endothelial Shear Stress Simulation: Does It Matter?. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 835270.	1.1	9
30	External Validation of the FREEDOM Score for Individualized Decision Making Between CABG and PCI. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1458-1473.	1.2	3
31	Quantitative Angiographic Assessment of Aortic Regurgitation Following 11 TAVR Devices: An Update of a Multicenter Pooled Analysis. , 2022, , 100037.		5
32	Impact of preprocedural biological markers on 10-year mortality in the SYNTAXES trial. <i>EuroIntervention</i> , 2022, 17, 1477-1487.	1.4	6
33	Sirolimus-eluting stents with ultrathin struts versus everolimus-eluting stents for patients undergoing percutaneous coronary intervention: final three-year results of the TALENT trial. <i>EuroIntervention</i> , 2022, 18, 492-502.	1.4	8
34	Ticagrelor monotherapy versus aspirin monotherapy at 12 months after percutaneous coronary intervention: a landmark analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2022, 18, e377-e388.	1.4	16
35	The 20-year â€•imaging sagaâ€•for transcatheter aortic valve implantation: A viewpoint. <i>Archives of Cardiovascular Diseases</i> , 2022, 115, 225-230.	0.7	0
36	Impact of proton pump inhibitors on efficacy of antiplatelet strategies with ticagrelor or aspirin after percutaneous coronary intervention: Insights from the GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 100, 72-82.	0.7	4

#	ARTICLE	IF	CITATIONS
37	Letter by Kawashima et al Regarding Article, "Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention in Patients With Chronic Total Occlusion and Multivessel Disease": Circulation: Cardiovascular Interventions, 2022, 15, e012080.	1.4	0
38	Predicted and Observed Mortality at 10 Years in Patients With Bifurcation Lesions in the SYNTAX Trial. JACC: Cardiovascular Interventions, 2022, 15, 1231-1242.	1.1	16
39	Definitions and Standardized Endpoints for Treatment of Coronary Bifurcations. Journal of the American College of Cardiology, 2022, 80, 63-88.	1.2	25
40	Periprocedural Outcomes Associated With Use of a Left Atrial Appendage Occlusion Device in China. JAMA Network Open, 2022, 5, e2214594.	2.8	14
41	P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary intervention. Nature Reviews Cardiology, 2022, 19, 829-844.	6.1	30
42	Mortality after multivessel revascularisation involving the proximal left anterior descending artery. Heart, 2022, 108, 1784-1791.	1.2	7
43	Site vs. core laboratory variability in computed tomographic angiography-derived SYNTAX scores in the SYNTAX III trial. European Heart Journal Cardiovascular Imaging, 2021, 22, 1063-1071.	0.5	2
44	Impact of lesion preparation strategies on outcomes of left main PCI: The EXCEL trial. Catheterization and Cardiovascular Interventions, 2021, 98, 24-32.	0.7	7
45	Antithrombotic regimens for percutaneous coronary intervention of the left main coronary artery: The EXCEL trial. Catheterization and Cardiovascular Interventions, 2021, 97, 766-773.	0.7	4
46	Influence of Bleeding Risk on Outcomes of Radial and Femoral Access for Percutaneous Coronary Intervention: An Analysis From the GLOBAL LEADERS Trial. Canadian Journal of Cardiology, 2021, 37, 122-130.	0.8	4
47	Commentary regarding the article by Gragnano et al. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, e64-e64.	1.4	2
48	The ultra-thin strut sirolimus-eluting coronary stent: SUPRAFLEX. Future Cardiology, 2021, 17, 227-237.	0.5	5
49	Rationale and design of a randomized clinical trial comparing safety and efficacy of myval transcatheter heart valve versus contemporary transcatheter heart valves in patients with severe symptomatic aortic valve stenosis: The LANDMARK trial. American Heart Journal, 2021, 232, 23-38.	1.2	28
50	Usefulness of updated logistic clinical SYNTAX score based on MI-SYNTAX score in patients with ST-elevation myocardial infarction. Catheterization and Cardiovascular Interventions, 2021, 97, E919-E928.	0.7	4
51	Mortality 10 Years After Percutaneous or Surgical Revascularization in Patients With Total Coronary Artery Occlusions. Journal of the American College of Cardiology, 2021, 77, 529-540.	1.2	17
52	Regional variation in patients and outcomes in the GLOBAL LEADERS trial. International Journal of Cardiology, 2021, 324, 30-37.	0.8	4
53	Utility of the dual antiplatelet therapy score to guide antiplatelet therapy: A systematic review and meta-analysis. Catheterization and Cardiovascular Interventions, 2021, 97, 569-578.	0.7	6
54	Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A) Tj ETQq0 0 0 rgBT Overlock 10 Tf 50 5		

#	ARTICLE	IF	CITATIONS
55	A Prospective Multicenter Randomized Trial to Assess the Effectiveness of the MagicTouch Sirolimus-Coated Balloon in Small Vessels: Rationale and Design of the TRANSFORM I Trial. <i>Cardiovascular Revascularization Medicine</i> , 2021, 25, 29-35.	0.3	10
56	Ticagrelor monotherapy following percutaneous coronary intervention for acute coronary syndrome in TWILIGHT patients: still a future for aspirin?. <i>European Heart Journal</i> , 2021, 42, 2708-2709.	1.0	3
57	Ten-year all-cause death following percutaneous or surgical revascularization in patients with prior cerebrovascular disease: insights from the SYNTAX Extended Survival study. <i>Clinical Research in Cardiology</i> , 2021, 110, 1543-1553.	1.5	4
58	Relationship between insulin resistance, coronary plaque, and clinical outcomes in patients with acute coronary syndromes: an analysis from the PROSPECT study. <i>Cardiovascular Diabetology</i> , 2021, 20, 10.	2.7	12
59	Quantitative Angiographic Assessment of Aortic Regurgitation after Transcatheter Aortic Valve Implantation among Three Balloon-Expandable Valves. <i>Global Heart</i> , 2021, 16, 20.	0.9	21
60	Quantitative Angiographic Assessment of Aortic Regurgitation After Transcatheter Implantation of the Venus A-valve: Comparison with Other Self-Expanding Valves and Impact of a Learning Curve in a Single Chinese Center. <i>Global Heart</i> , 2021, 16, 54.	0.9	5
61	Invasive Coronary Physiology After Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 237-246.	1.1	21
62	A deep learning methodology for the automated detection of end-diastolic frames in intravascular ultrasound images. <i>International Journal of Cardiovascular Imaging</i> , 2021, 37, 1825-1837.	0.7	11
63	Concerns with the new SYNTAX score – Authors' reply. <i>Lancet</i> , The, 2021, 397, 795-796.	6.3	11
64	Predicting 2-year all-cause mortality after contemporary <sc>PCI</sc>: Updating the logistic clinical <sc>SYNTAX</sc> score. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 1287-1297.	0.7	6
65	Coronary interventions in 2020: the year in review. <i>EuroIntervention</i> , 2021, 16, e1215-e1226.	1.4	1
66	Comparison of Investigator-Reported and Clinical Event Committee-Adjudicated Outcome Events in GLASSY. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006581.	0.9	10
67	Usability of Fantom Encore® scaffold in non-complex bifurcations – Analysis in bench models. <i>Catheterization and Cardiovascular Interventions</i> , 2021, , .	0.7	1
68	Impact of chronic obstructive pulmonary disease on 10-year mortality after percutaneous coronary intervention and bypass surgery for complex coronary artery disease: insights from the SYNTAX Extended Survival study. <i>Clinical Research in Cardiology</i> , 2021, 110, 1083-1095.	1.5	10
69	The era of single angiographic view for physiological assessment has come. Is simplification the ultimate sophistication?. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 964-965.	0.7	3
70	Online three-dimensional OFDI-guided versus angiography-guided PCI in bifurcation lesions: design and rationale of the randomised OPTIMUM trial. <i>EuroIntervention</i> , 2021, 16, 1333-1341.	1.4	9
71	Outpatient Versus Inpatient Percutaneous Coronary Intervention in Patients With Left Main Disease (from the EXCEL Trial). <i>American Journal of Cardiology</i> , 2021, 143, 21-28.	0.7	0
72	Multi-modality intravascular imaging for guiding coronary intervention and assessing coronary atheroma: the Novasight Hybrid IVUS-OCT system. <i>Minerva Cardiology and Angiology</i> , 2021, 69, 655-670.	0.4	5

#	ARTICLE	IF	CITATIONS
73	10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1165-1178.	1.2	32
74	Current perspectives on bioresorbable scaffolds in coronary intervention and other fields. <i>Expert Review of Medical Devices</i> , 2021, 18, 351-366.	1.4	13
75	Identification of vulnerable plaques and patients by intracoronary near-infrared spectroscopy and ultrasound (PROSPECT II): a prospective natural history study. <i>Lancet, The</i> , 2021, 397, 985-995.	6.3	208
76	Prospective Multicenter Randomized All-Comers Trial to Assess the Safety and Effectiveness of the Ultra-Thin Strut Sirolimus-Eluting Coronary Stent Supraflex. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010312.	1.4	10
77	Online Quantitative Aortographic Assessment of Aortic Regurgitation After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 531-538.	1.1	8
78	Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, 7, 547-556.	1.4	3
79	White blood cell count and clinical outcomes after left main coronary artery revascularization. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, 45-51.	0.3	0
80	Impact of renin-angiotensin system inhibitors after revascularization of patients with left main coronary artery disease. <i>Coronary Artery Disease</i> , 2021, Publish Ahead of Print, 37-44.	0.3	1
81	Impact of stent length and diameter on 10-year mortality in the SYNTAXES trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E379-E387.	0.7	10
82	External validation of the GRACE risk score 2.0 in the contemporary all-comers GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, E513-E522.	0.7	1
83	P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials. <i>BMJ, The</i> , 2021, 373, n1332.	3.0	144
84	Angiography-Based 4-Dimensional Superficial Wall Strain and Stress: A New Diagnostic Tool in the Catheterization Laboratory. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 667310.	1.1	5
85	10-Year Follow-Up After Revascularization in Elderly Patients With Complex Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2761-2773.	1.2	32
86	Percutaneous Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 78, 384-407.	1.2	16
87	Impact of Body Composition Indices on Ten-year Mortality After Revascularization of Complex Coronary Artery Disease (From the Syntax Extended Survival Trial). <i>American Journal of Cardiology</i> , 2021, 151, 30-38.	0.7	6
88	Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI: a post hoc analysis of the randomized GLOBAL LEADERS trial. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 756-773.	0.4	1
89	Impact of Optimal Medical Therapy on 10-Year Mortality After Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2021, 78, 27-38.	1.2	41
90	Coronary artery bypass grafting versus percutaneous coronary intervention in ischaemic heart failure. Can reliable treatment decisions in high-risk patients be based on non-randomized data?. <i>European Heart Journal</i> , 2021, 42, 2665-2669.	1.0	5

#	ARTICLE	IF	CITATIONS
91	Validation of Prosthetic Mitral Regurgitation Quantification Using NovelÂAngiographic Platform byÂMockÂCirculation. JACC: Cardiovascular Interventions, 2021, 14, 1523-1534.	1.1	3
92	Ten-Year All-Cause Death According to Completeness of Revascularization in Patients With Three-Vessel Disease or Left Main Coronary Artery Disease: Insights From the SYNTAX Extended Survival Study. Circulation, 2021, 144, 96-109.	1.6	41
93	Coronary Computed Tomographic Angiography for Complete Assessment of Coronary Artery Disease. Journal of the American College of Cardiology, 2021, 78, 713-736.	1.2	66
94	Coronary plaque features on CTA can identify patients at increased risk of cardiovascular events. Current Opinion in Cardiology, 2021, 36, 784-792.	0.8	8
95	Impact of established cardiovascular disease on 10-year death after coronary revascularization for complex coronary artery disease. Clinical Research in Cardiology, 2021, 110, 1680-1691.	1.5	4
96	Have We Overdefined Periprocedural Myocardial Infarction to the Point ofÂExtinction?. JACC: Cardiovascular Interventions, 2021, 14, 1635-1638.	1.1	7
97	Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data. European Heart Journal, 2021, 43, 18-28.	1.0	59
98	Ten-year all-cause death after percutaneous or surgical revascularization in diabetic patients with complex coronary artery disease. European Heart Journal, 2021, 43, 56-67.	1.0	23
99	Ten-year all-cause mortality following staged percutaneous revascularization in patients with complex coronary artery disease. Cardiovascular Revascularization Medicine, 2021, , .	0.3	0
100	Editorial: Advances in Intravascular Imaging. Frontiers in Cardiovascular Medicine, 2021, 8, 764378.	1.1	0
101	Advanced deep learning methodology for accurate, real-time segmentation of high-resolution intravascular ultrasound images. International Journal of Cardiology, 2021, 339, 185-191.	0.8	14
102	External Validation of the SYNTAXÂScoreÂII 2020. Journal of the American College of Cardiology, 2021, 78, 1227-1238.	1.2	30
103	Operator preference and determinants of size selection when additional intermediate-size aortic transcatheter heart valves are made available. International Journal of Cardiology, 2021, 338, 168-173.	0.8	11
104	Efficacy and Safety of Ticagrelor Monotherapy by Clinical Presentation: Preâ€Specified Analysis of the GLOBAL LEADERS Trial. Journal of the American Heart Association, 2021, 10, e015560.	1.6	18
105	Trade-off Between Bleeding and Thrombotic Risk in Patients With Academic Research Consortium for High Bleeding Risk. JAMA Cardiology, 2021, 6, 1092.	3.0	3
106	A prospective multicenter validation study for a novel angiography-derived physiological assessment software: Rationale and design of the radiographic imaging validation and evaluation for Anglo-iFR (ReVEAL iFR) study. American Heart Journal, 2021, 239, 19-26.	1.2	4
107	Impact of major infections on 10-year mortality after revascularization in patients with complex coronary artery disease. International Journal of Cardiology, 2021, 341, 9-12.	0.8	1
108	Drugâ€Eluting or Bareâ€Metal Stents for Left Anterior Descending or Left Main Coronary Artery Revascularization. Journal of the American Heart Association, 2021, 10, e018828.	1.6	4



#	ARTICLE	IF	CITATIONS
109	Comparison of Clinically Adjudicated Versus Flow-Based Adjudication of Revascularization Events in Randomized Controlled Trials. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e008055.	0.9	4
110	Paravalvular Aortic Regurgitation Severity Assessed by Quantitative Aortography: ACURATE neo2 versus ACURATE neo Transcatheter Aortic Valve Implantation. <i>Journal of Clinical Medicine</i> , 2021, 10, 4627.	1.0	11
111	Angiographic quantitative flow ratio-guided coronary intervention (FAVOR III China): a multicentre, randomised, sham-controlled trial. <i>Lancet, The</i> , 2021, 398, 2149-2159.	6.3	175
112	Optical Coherence Tomography-Derived Changes in Plaque Structural Stress Over the Cardiac Cycle: A New Method for Plaque Biomechanical Assessment. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 715995.	1.1	8
113	Reply. <i>Journal of the American College of Cardiology</i> , 2021, 78, e173-e174.	1.2	0
114	Percutaneous coronary intervention with drug-eluting stents versus coronary artery bypass grafting in left main coronary artery disease: an individual patient data meta-analysis. <i>Lancet, The</i> , 2021, 398, 2247-2257.	6.3	115
115	Understanding the past, getting prepared for the future. (Going from in vivo to in vitro to in silico). <i>EuroIntervention</i> , 2021, 17, 787-789.	1.4	0
116	Comparative Quantitative Aortographic Assessment of Regurgitation in Patients Treated With VitaFlow Transcatheter Heart Valve vs. Other Self-Expanding Systems. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 747174.	1.1	3
117	Chronic haemodynamic performance of a biorestorative transcatheter heart valve in an ovine model. <i>EuroIntervention</i> , 2021, 17, e1009-e1018.	1.4	4
118	The impact of plaque type on strut embedment/protrusion and shear stress distribution in bioresorbable scaffold. <i>European Heart Journal Cardiovascular Imaging</i> , 2020, 21, 454-462.	0.5	5
119	Clinical outcomes at 2 years of the Absorb bioresorbable vascular scaffold versus the Xience drug-eluting metallic stent in patients presenting with acute coronary syndrome versus stable coronary disease—AIDA trial substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 89-96.	0.7	4
120	Uncertainties and challenges in surgical and transcatheter tricuspid valve therapy: a state-of-the-art expert review. <i>European Heart Journal</i> , 2020, 41, 1932-1940.	1.0	43
121	Two years clinical outcomes with the state-of-the-art PCI for the treatment of bifurcation lesions: A subanalysis of the SYNTAX II study. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 10-17.	0.7	1
122	Clinical relevance of ticagrelor monotherapy following 1-month dual antiplatelet therapy after bifurcation percutaneous coronary intervention: Insight from GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 100-111.	0.7	16
123	Utility of Multimodality Intravascular Imaging and the Local Hemodynamic Forces to Predict Atherosclerotic Disease Progression. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1021-1032.	2.3	32
124	Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 21.	3.0	49
125	Usefulness of Discharge Resting Heart Rate to Predict Adverse Cardiovascular Outcomes in Patients With Left Main Coronary Artery Disease Revascularized With Percutaneous Coronary Intervention vs Coronary Artery Bypass Grafting (from the EXCEL Trial). <i>American Journal of Cardiology</i> , 2020, 125, 169-175.	0.7	1
126	Association of Pulse Pressure With Clinical Outcomes in Patients Under Different Antiplatelet Strategies After Percutaneous Coronary Intervention: Analysis of GLOBAL LEADERS. <i>Canadian Journal of Cardiology</i> , 2020, 36, 747-755.	0.8	2



#	ARTICLE	IF	CITATIONS
127	Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 222-230.	1.4	7
128	Cracking (the code of) coronary artery calcification to win the last battle of percutaneous coronary intervention: still in the middle of a rocky road. <i>European Heart Journal</i> , 2020, 41, 797-800.	1.0	3
129	Impact of established cardiovascular disease on outcomes in the randomized global leaders trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1369-1378.	0.7	6
130	Incidence and Prognostic Impact of Atrial Fibrillation After Discharge Following Revascularization for Significant Left Main Coronary Artery Narrowing. <i>American Journal of Cardiology</i> , 2020, 125, 500-506.	0.7	3
131	The influence of implantation techniques on lesion oriented-outcomes in Absorb BVS and Xience EES lesions treated in routine clinical practice at complete three year follow-up: AIDA trial QCA substudy. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 565-575.	0.7	0
132	The year in cardiology: coronary interventions. <i>European Heart Journal</i> , 2020, 41, 394-405.	1.0	8
133	Impact of recruitment and retention on all-cause mortality in a large all-comers randomised controlled trial: insights from the GLOBAL LEADERS trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 918-929.	1.5	3
134	Association between post-percutaneous coronary intervention bivalirudin infusion and net adverse clinical events: a post hoc analysis of the GLOBAL LEADERS study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020, 6, 22-30.	1.4	7
135	Sex Differences in All-Cause Mortality in the Decade Following Complex Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2020, 76, 889-899.	1.2	30
136	Ticagrelor monotherapy in patients with concomitant diabetes mellitus and chronic kidney disease: a post hoc analysis of the GLOBAL LEADERS trial. <i>Cardiovascular Diabetology</i> , 2020, 19, 179.	2.7	14
137	Endothelial shear stress and vascular remodeling in bioresorbable scaffold and metallic stent. <i>Atherosclerosis</i> , 2020, 312, 79-89.	0.4	3
138	Aspirin-Free Prasugrel Monotherapy Following Coronary Artery Stenting in Patients With Stable CAD. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2251-2262.	1.1	70
139	Redevelopment and validation of the SYNTAX score II to individualise decision making between percutaneous and surgical revascularisation in patients with complex coronary artery disease: secondary analysis of the multicentre randomised controlled SYNTAXES trial with external cohort validation. <i>Lancet. The</i> , 2020, 396, 1399-1412.	6.3	120
140	The year in cardiology: coronary interventions. <i>SA Heart Journal</i> , 2020, 17, .	0.0	0
141	The revolution project: replacing coronary artery angiography with coronary computed tomography with functional evaluation. <i>European Heart Journal Supplements</i> , 2020, 22, L15-L18.	0.0	2
142	Imaging and 2-year clinical outcomes of thin strut sirolimus-eluting bioresorbable vascular scaffold: The MeRes extend trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 98, 1102-1110.	0.7	1
143	A Randomized Trial Evaluating Online 3-Dimensional Optical Frequency Domain Imaging-Guided Percutaneous Coronary Intervention in Bifurcation Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2020, 13, e009183.	1.4	19
144	Efficacy and safety of one-month DAPT followed by 23-month ticagrelor monotherapy in patients undergoing proximal LAD stenting: Insights from the GLOBAL LEADERS trial. <i>International Journal of Cardiology</i> , 2020, 320, 27-34.	0.8	4

#	ARTICLE	IF	CITATIONS
145	The Impact of Coronary Physiology on Contemporary Clinical Decision Making. JACC: Cardiovascular Interventions, 2020, 13, 1617-1638.	1.1	60
146	Advances in IVUS/OCT and Future Clinical Perspective of Novel Hybrid Catheter System in Coronary Imaging. Frontiers in Cardiovascular Medicine, 2020, 7, 119.	1.1	65
147	Comparative Methodological Assessment of the Randomized GLOBAL LEADERS Trial Using Total Ischemic and Bleeding Events. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006660.	0.9	11
148	Three-year clinical outcomes of the absorb bioresorbable vascular scaffold compared to Xience everolimus-eluting stent in routine PCI in patients with diabetes mellitus" AIDA sub-study. Catheterization and Cardiovascular Interventions, 2020, 98, 713-720.	0.7	1
149	Impact of Bleeding and Myocardial Infarction on Mortality in All-Coroner Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2020, 13, e009177.	1.4	15
150	Lifelong Aspirin for All in the Secondary Prevention of Chronic Coronary Syndrome. Circulation, 2020, 142, 1579-1590.	1.6	28
151	Impact of Peri-Procedural Myocardial Infarction on Outcomes After Revascularization. Journal of the American College of Cardiology, 2020, 76, 1622-1639.	1.2	73
152	Implications of Alternative Definitions of Peri-Procedural Myocardial Infarction After Coronary Revascularization. Journal of the American College of Cardiology, 2020, 76, 1609-1621.	1.2	75
153	Impact of white blood cell count on clinical outcomes in patients treated with aspirin-free ticagrelor monotherapy after percutaneous coronary intervention: insights from the GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2020, , .	1.4	10
154	Contemporary rationale for non-invasive imaging of adverse coronary plaque features to identify the vulnerable patient: A Position Paper from the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology and the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging, 2020, 21, 1177-1183.	0.5	29
155	The state-of-the-art coronary stent with crystallized sirolimus: the MiStent technology and its clinical program. Future Cardiology, 2020, 17, 593-607.	0.5	1
156	Safety and feasibility evaluation of planning and execution of surgical revascularisation solely based on coronary CTA and FFR<sub>CT</sub> in patients with complex coronary artery disease: study protocol of the FASTTRACK CABG study. BMJ Open, 2020, 10, e038152.	0.8	24
157	Long-Term Outcomes After Revascularization for Stable Ischemic Heart Disease. Circulation: Cardiovascular Interventions, 2020, 13, e008565.	1.4	17
158	Vulnerable plaques and patients: state-of-the-art. European Heart Journal, 2020, 41, 2997-3004.	1.0	98
159	Twilight, the Dawn of a New Era of Aspirin-Free PCI?. Journal of the American College of Cardiology, 2020, 75, 2425-2429.	1.2	6
160	Drug-eluting bioresorbable scaffolds in cardiovascular disease, peripheral artery and gastrointestinal fields: a clinical update. Expert Opinion on Drug Delivery, 2020, 17, 931-945.	2.4	6
161	Final 3-Year Outcomes of MiStent Biodegradable Polymer Crystalline Sirolimus-Eluting Stent Versus Xience Permanent Polymer Everolimus-Eluting Stent. Circulation: Cardiovascular Interventions, 2020, 13, e008737.	1.4	17
162	European Bifurcation Club white paper on stenting techniques for patients with bifurcated coronary artery lesions. Catheterization and Cardiovascular Interventions, 2020, 96, 1067-1079.	0.7	57

#	ARTICLE	IF	CITATIONS
163	Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study. <i>European Heart Journal</i> , 2020, 41, 2058-2066.	1.0	299
164	Coronary Calcification and Long-Term Outcomes According to Drug-Eluting Stent Generation. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1417-1428.	1.1	77
165	Clinical Outcomes Following Coronary Bifurcation PCI Techniques. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1432-1444.	1.1	78
166	Predictive value of the QFR in detecting vulnerable plaques in non-flow limiting lesions: a combined analysis of the PROSPECT and IBIS-4 study. <i>International Journal of Cardiovascular Imaging</i> , 2020, 36, 993-1002.	0.7	6
167	Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1087-1095.	1.8	14
168	Prognostic Impact of Race in Patients Undergoing PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1586-1595.	1.1	49
169	Stent-Related Adverse Events >1 Year After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 590-604.	1.2	160
170	DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 634-646.	1.1	17
171	Impact of left ventricular ejection fraction on clinical outcomes after left main coronary artery revascularization: results from the randomized EXCEL trial. <i>European Journal of Heart Failure</i> , 2020, 22, 871-879.	2.9	27
172	Mortality After Repeat Revascularization Following PCI or CABG for Left Main Disease. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 375-387.	1.1	55
173	Association of diabetes with outcomes in patients undergoing contemporary percutaneous coronary intervention: Pre-specified subgroup analysis from the randomized GLOBAL LEADERS study. <i>Atherosclerosis</i> , 2020, 295, 45-53.	0.4	36
174	Impact of renal function on clinical outcomes after PCI in ACS and stable CAD patients treated with ticagrelor: a prespecified analysis of the GLOBAL LEADERS randomized clinical trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 930-943.	1.5	14
175	The impact of pre-procedure heart rate on adverse clinical outcomes in patients undergoing percutaneous coronary intervention: Results from a 2-year follow-up of the GLOBAL LEADERS trial. <i>Atherosclerosis</i> , 2020, 303, 1-7.	0.4	1
176	Long-Term Outcomes in Women and Men Following Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1631-1640.	1.2	68
177	Quantitative Assessment of Acute Regurgitation Following TAVR. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1303-1311.	1.1	23
178	The Evolution of Data Fusion Methodologies Developed to Reconstruct Coronary Artery Geometry From Intravascular Imaging and Coronary Angiography Data: A Comprehensive Review. <i>Frontiers in Cardiovascular Medicine</i> , 2020, 7, 33.	1.1	11
179	Outcomes After Left Main Coronary Artery Revascularization by Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting According to Smoking Status. <i>American Journal of Cardiology</i> , 2020, 127, 16-24.	0.7	4
180	Usefulness of the updated logistic clinical SYNTAX score after percutaneous coronary intervention in patients with prior coronary artery bypass graft surgery: Insights from the GLOBAL LEADERS trial. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, E516-E526.	0.7	5

#	ARTICLE	IF	CITATIONS
181	Evaluation of the Efficacy of Computed Tomographic Coronary Angiography in Assessing Coronary Artery Morphology and Physiology: Rationale and Study Design. <i>Cardiology</i> , 2020, 145, 285-293.	0.6	9
182	The association of body mass index with long-term clinical outcomes after ticagrelor monotherapy following abbreviated dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a prespecified sub-analysis of the GLOBAL LEADERS Trial. <i>Clinical Research in Cardiology</i> , 2020, 109, 1125-1139.	1.5	14
183	Did the SYNTAX Score Pass the Test of Time?. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1207-1210.	1.1	1
184	Shear Stress Estimated by Quantitative Coronary Angiography Predicts Plaques Prone to Progress and Cause Events. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 2206-2219.	2.3	27
185	Major infections after bypass surgery and stenting for multivessel coronary disease in the randomised SYNTAX trial. <i>EuroIntervention</i> , 2020, 15, 1520-1526.	1.4	5
186	Impact of ticagrelor monotherapy on two-year clinical outcomes in patients with long stenting: a post hoc analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2020, 16, 634-644.	1.4	6
187	The SYNTAX score on its way out or towards artificial intelligence: part I. <i>EuroIntervention</i> , 2020, 16, 44-59.	1.4	26
188	The SYNTAX score on its way out or towards artificial intelligence: part II. <i>EuroIntervention</i> , 2020, 16, 60-75.	1.4	18
189	Defining device success for percutaneous coronary intervention trials: a position statement from the European Association of Percutaneous Cardiovascular Interventions of the European Society of Cardiology. <i>EuroIntervention</i> , 2020, 15, 1190-1198.	1.4	17
190	BuMA Supreme biodegradable polymer sirolimus-eluting stent versus a durable polymer zotarolimus-eluting coronary stent: three-year clinical outcomes of the PIONEER trial. <i>EuroIntervention</i> , 2020, 16, e900-e903.	1.4	4
191	Ticagrelor monotherapy beyond one month after PCI in ACS or stable CAD in elderly patients: a pre-specified analysis of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2020, 15, e1605-e1614.	1.4	20
192	Quantitative aortography assessment of aortic regurgitation. <i>EuroIntervention</i> , 2020, 16, e738-e756.	1.4	8
193	Ticagrelor alone or conventional dual antiplatelet therapy in patients with stable or acute coronary syndromes. <i>EuroIntervention</i> , 2020, 16, 627-633.	1.4	18
194	A randomised controlled trial of the sirolimus-eluting biodegradable polymer ultra-thin Supraflex stent versus the everolimus-eluting biodegradable polymer SYNERGY stent for three-vessel coronary artery disease: rationale and design of the Multivessel TALENT trial. <i>EuroIntervention</i> , 2020, 16, e997-e1004.	1.4	6
195	Combining anatomy and physiology: New angiography-based and computed tomography coronary angiography-derived fractional flow reserve indices. <i>Cardiology Journal</i> , 2020, 27, 225-229.	0.5	5
196	The usefulness of cardiac CT integrated with FFRCT for planning myocardial revascularization in complex coronary artery disease: a lesson from SYNTAX studies. <i>Cardiovascular Diagnosis and Therapy</i> , 2020, 10, 2036-2047.	0.7	2
197	The year in cardiology: coronary interventions – The year in cardiology 2019. <i>Cardiologia Croatica</i> , 2020, 15, 114-131.	0.0	1
198	Angiographic derived endothelial shear stress: a new predictor of atherosclerotic disease progression. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 314-322.	0.5	11

#	ARTICLE	IF	CITATIONS
199	Standardized classification and framework for reporting, interpreting, and analysing medication non-adherence in cardiovascular clinical trials: a consensus report from the Non-adherence Academic Research Consortium (NARC). <i>European Heart Journal</i> , 2019, 40, 2070-2085.	1.0	64
200	Impact of long-term ticagrelor monotherapy following 1-month dual antiplatelet therapy in patients who underwent complex percutaneous coronary intervention: insights from the Global Leaders trial. <i>European Heart Journal</i> , 2019, 40, 2595-2604.	1.0	93
201	Off-Pump Versus On-Pump Bypass Surgery for Left Main Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 74, 729-740.	1.2	28
202	Comparison of Major Adverse Cardiac Events Between Instantaneous Wave-Free Ratio and Fractional Flow Reserve-Guided Strategy in Patients With or Without Type 2 Diabetes. <i>JAMA Cardiology</i> , 2019, 4, 857.	3.0	25
203	Stroke After Coronary Artery Bypass Grafting and Percutaneous Coronary Intervention: Incidence, Pathogenesis, and Outcomes. <i>Journal of the American Heart Association</i> , 2019, 8, e013032.	1.6	45
204	Association of Coronary Anatomical Complexity With Clinical Outcomes After Percutaneous or Surgical Revascularization in the Veterans Affairs Clinical Assessment Reporting and Tracking Program. <i>JAMA Cardiology</i> , 2019, 4, 727.	3.0	22
205	Sex Differences in Instantaneous Wave-Free Ratio or Fractional Flow Reserve-Guided Revascularization Strategy. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2035-2046.	1.1	26
206	Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2223-2234.	1.2	101
207	Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Multivessel PCI. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2015-2027.	1.2	23
208	Impact of non-respect of SYNTAX score II recommendation for surgery in patients with left main coronary artery disease treated by percutaneous coronary intervention: an EXCEL substudy. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 57, 676-683.	0.6	10
209	Ascertainment of Silent Myocardial Infarction in Patients Undergoing Percutaneous Coronary Intervention (from the GLOBAL LEADERS Trial). <i>American Journal of Cardiology</i> , 2019, 124, 1833-1840.	0.7	5
210	Comparison of a Complete Percutaneous Versus Surgical Approach to Aortic Valve Replacement and Revascularization in Patients at Intermediate Surgical Risk. <i>Circulation</i> , 2019, 140, 1296-1305.	1.6	59
211	Percutaneous coronary intervention versus coronary artery bypass grafting in patients with three-vessel or left main coronary artery disease: 10-year follow-up of the multicentre randomised controlled SYNTAX trial. <i>Lancet</i> , 2019, 394, 1325-1334.	6.3	406
212	Expert recommendations on the assessment of wall shear stress in human coronary arteries: existing methodologies, technical considerations, and clinical applications. <i>European Heart Journal</i> , 2019, 40, 3421-3433.	1.0	178
213	Benefit and Risks of Aspirin in Addition to Ticagrelor in Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 1092.	3.0	97
214	Time-Varying Outcomes With the Absorb Bioresorbable Vascular Scaffold During 5-Year Follow-up. <i>JAMA Cardiology</i> , 2019, 4, 1261.	3.0	71
215	Clinical Implication of Quantitative Flow Ratio After Percutaneous Coronary Intervention for 3-Vessel Disease. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2064-2075.	1.1	71
216	Five-Year Outcomes after PCI or CABG for Left Main Coronary Disease. <i>New England Journal of Medicine</i> , 2019, 381, 1820-1830.	13.9	523

#	ARTICLE	IF	CITATIONS
217	Clinical Events After Deferral of LAD Revascularization Following Physiological Coronary Assessment. <i>Journal of the American College of Cardiology</i> , 2019, 73, 444-453.	1.2	35
218	Impact of post-procedural minimal stent area on 2-year clinical outcomes in the SYNTAX II trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E225-E234.	0.7	26
219	Quantitative Assessment of Aortic Regurgitation After Transcatheter Aortic Valve Replacement With Videodensitometry in a Large, Real-World Study Population. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 216-218.	1.1	15
220	Mechanical properties and performances of contemporary drug-eluting stent: focus on the metallic backbone. <i>Expert Review of Medical Devices</i> , 2019, 16, 211-228.	1.4	27
221	Serial Optical Coherence Tomography at Baseline, 7 Days, and 1, 3, 6 and 12 Months After Bioresorbable Scaffold Implantation in a Growing Porcine Model. <i>Circulation Journal</i> , 2019, 83, 556-566.	0.7	1
222	Angiography-Derived Fractional Flow Reserve in the SYNTAX II Trial. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 259-270.	1.1	46
223	Outcomes of left main revascularization in patients with acute coronary syndromes and stable ischemic heart disease: Analysis from the EXCEL trial. <i>American Heart Journal</i> , 2019, 214, 9-17.	1.2	9
224	Dyspnoea in the GLOBAL LEADERS trial – Authors' reply. <i>Lancet, The</i> , 2019, 393, 2393-2394.	6.3	3
225	Contemporary Outcomes Following Coronary Artery Bypass Graft Surgery for Left Main Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1877-1886.	1.2	33
226	Clinical practice and ethics vs. statistics: considerations on Heart Team's decision testing study. <i>European Heart Journal</i> , 2019, 40, 1816-1817.	1.0	1
227	Impact of left ventricular function on clinical outcomes among patients with coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2019, 26, 1273-1284.	0.8	16
228	Feasibility of planning coronary artery bypass grafting based only on coronary computed tomography angiography and CT-derived fractional flow reserve: a pilot survey of the surgeons involved in the randomized SYNTAX III Revolution trial. <i>Interactive Cardiovascular and Thoracic Surgery</i> , 2019, 29, 209-216.	0.5	24
229	Long-term impact of diabetes in patients with ST-segment elevation myocardial infarction: Insights from the EXAMINATION randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 917-925.	0.7	5
230	Implications of the local haemodynamic forces on the phenotype of coronary plaques. <i>Heart</i> , 2019, 105, 1078-1086.	1.2	14
231	The relationship of pre-procedural Dmax based sizing to lesion level outcomes in Absorb BVS and Xience EES treated patients in the AIDA trial. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 1189-1198.	0.7	6
232	Rationale and design of a prospective substudy of clinical endpoint adjudication processes within an investigator-reported randomised controlled trial in patients with coronary artery disease: the GLOBAL LEADERS Adjudication Sub-Study (GLASSY). <i>BMJ Open</i> , 2019, 9, e026053.	0.8	18
233	Impact of large periprocedural myocardial infarction on mortality after percutaneous coronary intervention and coronary artery bypass grafting for left main disease: an analysis from the EXCEL trial. <i>European Heart Journal</i> , 2019, 40, 1930-1941.	1.0	65
234	Bypass Surgery or Stenting for Left Main Coronary Artery Disease in Patients With Diabetes. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1616-1628.	1.2	60



#	ARTICLE	IF	CITATIONS
235	Predictive ability of ACEF and ACEF II score in patients undergoing percutaneous coronary intervention in the GLOBAL LEADERS study. <i>International Journal of Cardiology</i> , 2019, 286, 43-50.	0.8	19
236	PCI and CABG for Treating Stable Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2019, 73, 964-976.	1.2	282
237	The time has come to use coronary computed tomography angiography in patients with multivessel coronary artery disease. <i>European Heart Journal</i> , 2019, 40, 1472-1472.	1.0	5
238	Safety and efficacy of a sirolimus-eluting coronary stent with ultra-thin strut for treatment of atherosclerotic lesions (TALENT): a prospective multicentre randomised controlled trial. <i>Lancet</i> , The, 2019, 393, 987-997.	6.3	72
239	Impact of Staging Percutaneous Coronary Intervention in Left Main Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 411-412.	1.1	5
240	Outcomes of patients with and without baseline lipid-lowering therapy undergoing revascularization for left main coronary artery disease. <i>Coronary Artery Disease</i> , 2019, 30, 143-149.	0.3	1
241	Efficacy and Safety of Stents in ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2019, 74, 2572-2584.	1.2	31
242	Efficacy and Reproducibility of Attenuation-Compensated Optical Coherence Tomography for Assessing External Elastic Membrane Border and Plaque Composition in Native and Stented Segments: An In Vivo and Histology-Based Study. <i>Circulation Journal</i> , 2019, 84, 91-100.	0.7	5
243	Determining the Predominant Lesion in Patients With Severe Aortic Stenosis and Coronary Stenoses. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008263.	1.4	20
244	Impact of Fractional Flow Reserve Derived From Coronary Computed Tomography Angiography on Heart Team Treatment Decision-Making in Patients With Multivessel Coronary Artery Disease. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007607.	1.4	76
245	Outcomes following surgical revascularization with single versus bilateral internal thoracic arterial grafts in patients with left main coronary artery disease undergoing coronary artery bypass grafting: insights from the EXCEL trial. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 501-510.	0.6	18
246	Changes in Coronary Plaque Composition in Patients With Acute Myocardial Infarction Treated With High-Intensity Statin Therapy (IBIS-4). <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 1518-1528.	2.3	61
247	Impact of chronic obstructive pulmonary disease on prognosis after percutaneous coronary intervention and bypass surgery for left main coronary artery disease: an analysis from the EXCEL trial. <i>European Journal of Cardio-thoracic Surgery</i> , 2019, 55, 1144-1151.	0.6	6
248	Feasibility study of a synchronized diastolic injection with low contrast volume for proper quantitative assessment of aortic regurgitation in porcine models. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 963-970.	0.7	9
249	Post-implantation shear stress assessment: an emerging tool for differentiation of bioresorbable scaffolds. <i>International Journal of Cardiovascular Imaging</i> , 2019, 35, 409-418.	0.7	10
250	C-reactive protein and prognosis after percutaneous coronary intervention and bypass graft surgery for left main coronary artery disease: Analysis from the EXCEL trial. <i>American Heart Journal</i> , 2019, 210, 49-57.	1.2	13
251	Application of the MADS classification system in a omega mammoth-stent trial: Feasibility and preliminary clinical implications. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 57-63.	0.7	5
252	Three-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds: Final results of the ABSORB EXTEND trial. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E1-E7.	0.7	11

#	ARTICLE	IF	CITATIONS
253	Impact of Pre-Diabetes on Coronary Plaque Composition and Clinical Outcome in Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Imaging</i> , 2019, 12, 733-741.	2.3	17
254	Joint consensus on the use of OCT in coronary bifurcation lesions by the European and Japanese bifurcation clubs. <i>EuroIntervention</i> , 2019, 14, e1568-e1577.	1.4	51
255	A prospective multicentre randomised all-comers trial to assess the safety and effectiveness of the thin-strut sirolimus-eluting coronary stent SUPRAFLEX: rationale and design of the Thin Strut Sirolimus-eluting Stent in All Comers Population vs Everolimus-eluting Stent (TALENT) trial. <i>EuroIntervention</i> , 2019, 15, e362-e369.	1.4	9
256	Clinical outcomes of state-of-the-art percutaneous coronary revascularisation in patients with three-vessel disease: two-year follow-up of the SYNTAX II study. <i>EuroIntervention</i> , 2019, 15, e244-e252.	1.4	53
257	Validation of the updated logistic clinical SYNTAX score for all-cause mortality in the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e539-e546.	1.4	16
258	Patient-oriented composite endpoints and net adverse clinical events with ticagrelor monotherapy following percutaneous coronary intervention: insights from the randomised GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2019, 15, e1090-e1098.	1.4	16
259	Quantitative aortography for assessing aortic regurgitation after transcatheter aortic valve implantation: results of the multicentre ASSESS-REGURGE Registry. <i>EuroIntervention</i> , 2019, 15, 420-426.	1.4	17
260	Bioresorptive Valve for Transcatheter Aortic Valve Implantation: Tomorrow's World from Preclinical to Clinical. , 2019, , 539-547.		0
261	Mortality after coronary artery bypass grafting versus percutaneous coronary intervention with stenting for coronary artery disease: a pooled analysis of individual patient data. <i>Lancet</i> , The, 2018, 391, 939-948.	6.3	506
262	Determinants of success and hemodynamic impact of balloon postdilatation of self-expanding transcatheter aortic valves. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 945-953.	0.7	2
263	Mortality Following Nonemergent, Uncomplicated Target Lesion Revascularization After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 892-902.	1.1	48
264	B-Type Natriuretic Peptide Assessment in Patients Undergoing Revascularization for Left Main Coronary Artery Disease. <i>Circulation</i> , 2018, 138, 469-478.	1.6	25
265	hemodynamic analysis of a novel bioresorbable scaffold in porcine coronary artery model. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1084-1091.	0.7	5
266	Clinical, Angiographic, and Procedural Correlates of Very Late Absorb Scaffold Thrombosis. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 638-644.	1.1	20
267	Endothelial shear stress 5 years after implantation of a coronary bioresorbable scaffold. <i>European Heart Journal</i> , 2018, 39, 1602-1609.	1.0	33
268	Impact of Coronary Remodeling on Fractional Flow Reserve. <i>Circulation</i> , 2018, 137, 747-749.	1.6	20
269	A Novel Angiographic Quantification of Aortic Regurgitation After TAVR Provides an Accurate Estimation of Regurgitation Fraction Derived From Cardiac Magnetic Resonance Imaging. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 287-297.	1.1	37
270	New-Onset Atrial Fibrillation After PCI or CABG for Left Main Disease. <i>Journal of the American College of Cardiology</i> , 2018, 71, 739-748.	1.2	94

#	ARTICLE	IF	CITATIONS
271	Effects of Body Mass Index on Clinical Outcomes in Female Patients Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 68-76.	1.1	28
272	Effect of Increasing Stent Length on 3-Year Clinical Outcomes in Women Undergoing Percutaneous Coronary Intervention With New-Generation Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 53-65.	1.1	22
273	Left main coronary artery disease: pathophysiology, diagnosis, and treatment. <i>Nature Reviews Cardiology</i> , 2018, 15, 321-331.	6.1	73
274	Virtual Resting Pd/Pa From Coronary Angiography and Blood Flow Modelling: Diagnostic Performance Against Fractional Flow Reserve. <i>Heart Lung and Circulation</i> , 2018, 27, 377-380.	0.2	7
275	Risk and timing of clinical events according to diabetic status of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting stent: 2-year results from a propensity score matched comparison of ABSORB EXTEND and SPIRIT trials. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 387-395.	0.7	3
276	Fate of post-procedural malapposition of everolimus-eluting polymeric bioresorbable scaffold and everolimus-eluting cobalt chromium metallic stent in human coronary arteries: sequential assessment with optical coherence tomography in ABSORB Japan trial. <i>European Heart Journal Cardiovascular Imaging</i> , 2018, 19, 59-66.	0.5	21
277	Intravascular imaging in cardiovascular ageing. <i>Experimental Gerontology</i> , 2018, 109, 31-37.	1.2	3
278	Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up. <i>European Heart Journal</i> , 2018, 39, 295-302.	1.0	96
279	Diagnostic Accuracy of Coronary CT Angiography for the Evaluation of Bioresorbable Vascular Scaffolds. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 722-732.	2.3	12
280	Three-Year Outcomes With the Absorb Bioresorbable Scaffold. <i>Circulation</i> , 2018, 137, 464-479.	1.6	152
281	Two-year clinical outcomes of patients treated with overlapping absorb scaffolds: An analysis of the ABSORB EXTEND single-arm study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1202-1209.	0.7	3
282	Visual estimation versus different quantitative coronary angiography methods to assess lesion severity in bifurcation lesions. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 1263-1270.	0.7	10
283	Role of Low Endothelial Shear Stress and Plaque Characteristics in the Prediction of Nonculprit Major Adverse Cardiac Events. <i>JACC: Cardiovascular Imaging</i> , 2018, 11, 462-471.	2.3	124
284	A sirolimus-eluting bioabsorbable polymer-coated stent (MiStent) versus an everolimus-eluting durable polymer stent (Xience) after percutaneous coronary intervention (DESSOLVE III): a randomised, single-blind, multicentre, non-inferiority, phase 3 trial. <i>Lancet</i> , 2018, 391, 431-440.	6.3	70
285	Imaging assessment of bioresorbable vascular scaffolds. <i>Cardiovascular Intervention and Therapeutics</i> , 2018, 33, 11-22.	1.2	9
286	Fractional flow reserve at the crossroad between revascularization and medical therapy. <i>Cardiovascular Diagnosis and Therapy</i> , 2018, 8, 556-558.	0.7	1
287	Multimodality Imaging to Detect Vulnerable Plaque in Coronary Arteries and Its Clinical Application. , 2018, , .		1
288	Left Main Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Patients With Prior Cerebrovascular Disease. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2441-2450.	1.1	6

#	ARTICLE	IF	CITATIONS
289	Outcomes Among Patients Undergoing Distal Left Main Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e007007.	1.4	45
290	Coronary computed tomography angiography for heart team decision-making in multivessel coronary artery disease. <i>European Heart Journal</i> , 2018, 39, 3689-3698.	1.0	140
291	Prognostic Value of Intravascular Ultrasound in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 2003-2011.	1.2	38
292	Percutaneous coronary intervention or coronary artery bypass graft in left main coronary artery disease. <i>Journal of Cardiovascular Medicine</i> , 2018, 19, 554-563.	0.6	9
293	Long-Term Coronary Functional Assessment of the Infarct-Related Artery Treated With Everolimus-Eluting Bioresorbable Scaffolds or Everolimus-Eluting Metallic Stents. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1559-1571.	1.1	29
294	Role of Computed Tomography in Planning the Appropriate X-Ray Gantry for Quantitative Aortography of Post-transcatheter Aortic Valve Implantation Regurgitation. <i>Circulation Journal</i> , 2018, 82, 1943-1950.	0.7	7
295	Fractional Flow Reserve Derived From Computed Tomographic Angiography in Patients With Multivessel CAD. <i>Journal of the American College of Cardiology</i> , 2018, 71, 2756-2769.	1.2	92
296	The Long-Term Impact of Post-Procedural Asymmetry and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1013-1015.	1.1	2
297	Relationship between left main coronary artery plaque burden and nonleft main coronary atherosclerosis. <i>Coronary Artery Disease</i> , 2018, 29, 397-402.	0.3	3
298	Plasma concentrations of molecular lipid species predict long-term clinical outcome in coronary artery disease patients. <i>Journal of Lipid Research</i> , 2018, 59, 1729-1737.	2.0	105
299	Implications of the local hemodynamic forces on the formation and destabilization of neoatherosclerotic lesions. <i>International Journal of Cardiology</i> , 2018, 272, 7-12.	0.8	16
300	SYNTAX score II predicts long-term mortality in patients with one- or two-vessel disease. <i>PLoS ONE</i> , 2018, 13, e0200076.	1.1	9
301	Aspirin-free strategies in cardiovascular disease and cardioembolic stroke prevention. <i>Nature Reviews Cardiology</i> , 2018, 15, 480-496.	6.1	180
302	SYNTAX II and SYNTAX III trials: what is the take home message for surgeons?. <i>Annals of Cardiothoracic Surgery</i> , 2018, 7, 470-482.	0.6	17
303	Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease. <i>Journal of the American College of Cardiology</i> , 2018, 72, 754-765.	1.2	59
304	Safety of the Deferral of Coronary Revascularization on the Basis of Instantaneous Wave-Free Ratio and Fractional Flow Reserve Measurements in Stable Coronary Artery Disease and Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1437-1449.	1.1	111
305	Cardiovascular and Noncardiovascular Death After Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006488.	1.4	21
306	Inter-Technique Consistency and Prognostic Value of Intra-Procedural Angiographic and Echocardiographic Assessment of Aortic Regurgitation After Transcatheter Aortic Valve Implantation. <i>Circulation Journal</i> , 2018, 82, 2317-2325.	0.7	11

#	ARTICLE	IF	CITATIONS
307	Stroke Rates Following Surgical Versus Percutaneous Coronary Revascularization. <i>Journal of the American College of Cardiology</i> , 2018, 72, 386-398.	1.2	89
308	Mid-term outcomes of the Absorb BVS versus second-generation DES: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2018, 13, e0197119.	1.1	13
309	Defining Staged Procedures for Percutaneous Coronary Intervention Trials. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 823-832.	1.1	17
310	Imaging-guided pre-dilatation, stenting, post-dilatation: a protocolized approach highlighting the importance of intravascular imaging for implantation of bioresorbable scaffolds. <i>Expert Review of Cardiovascular Therapy</i> , 2018, 16, 431-440.	0.6	8
311	Coronary Hemodynamics in Patients With Severe Aortic Stenosis and Coronary Artery Disease Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 2019-2031.	1.1	88
312	Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. <i>Lancet</i> , 2018, 392, 940-949.	6.3	555
313	Diagnostic performance of angiography-derived fractional flow reserve: a systematic review and Bayesian meta-analysis. <i>European Heart Journal</i> , 2018, 39, 3314-3321.	1.0	116
314	Standardized End Point Definitions for Coronary Intervention Trials. <i>European Heart Journal</i> , 2018, 39, 2192-2207.	1.0	179
315	Standardized End Point Definitions for Coronary Intervention Trials: The Academic Research Consortium-2 Consensus Document. <i>Circulation</i> , 2018, 137, 2635-2650.	1.6	435
316	In vitro validation of coronary CT angiography for the evaluation of complex lesions. <i>EuroIntervention</i> , 2018, 13, e1823-e1830.	1.4	14
317	Videodensitometric quantification of paravalvular regurgitation of a transcatheter aortic valve: in vitro validation. <i>EuroIntervention</i> , 2018, 13, 1527-1535.	1.4	21
318	Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial. <i>EuroIntervention</i> , 2018, 13, 1939-1945.	1.4	7
319	Quality difference of neointima following the implantation of everolimus-eluting bioresorbable scaffolds and metallic stents in patients with ST-elevation myocardial infarction: quantitative assessments by light intensity, light attenuation, and backscatter on optical coherence tomography in the TROFL II trial. <i>EuroIntervention</i> , 2018, 14, 678-685.	1.4	12
320	Implantation techniques (predilatation, sizing, and post-dilatation) and the incidence of scaffold thrombosis and revascularisation in lesions treated with an everolimus-eluting bioresorbable vascular scaffold: insights from the AIDA trial. <i>EuroIntervention</i> , 2018, 14, e434-e442.	1.4	14
321	One-year outcomes of patients with severe aortic stenosis and an STS PROM of less than three percent in the SURTAVI trial. <i>EuroIntervention</i> , 2018, 14, 877-883.	1.4	59
322	A randomised comparison of healing response between the BuMA Supreme stent and the XIENCE stent at one-month and two-month follow-up: PIONEER-II OCT randomised controlled trial. <i>EuroIntervention</i> , 2018, 14, e1306-e1315.	1.4	16
323	Radial versus femoral artery access in patients undergoing PCI for left main coronary artery disease: analysis from the EXCEL trial. <i>EuroIntervention</i> , 2018, 14, 1104-1111.	1.4	11
324	Adiponectin in Relation to Coronary Plaque Characteristics on Radiofrequency Intravascular Ultrasound and Cardiovascular Outcome. <i>Arquivos Brasileiros De Cardiologia</i> , 2018, 111, 345-353.	0.3	3

#	ARTICLE	IF	CITATIONS
325	The Role of Quantitative Aortographic Assessment of Aortic Regurgitation by Videodensitometry in the Guidance of Transcatheter Aortic Valve Implantation. <i>Arquivos Brasileiros De Cardiologia</i> , 2018, 111, 193-202.	0.3	8
326	The ball is now in our court. <i>EuroIntervention</i> , 2018, 14, 739-741.	1.4	1
327	Biomechanical stress in coronary atherosclerosis: emerging insights from computational modelling. <i>European Heart Journal</i> , 2017, 38, ehv689.	1.0	87
328	Prediction of atherosclerotic disease progression using LDL transport modelling: a serial computed tomographic coronary angiographic study. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 11-18.	0.5	40
329	Hybrid intravascular imaging: recent advances, technical considerations, and current applications in the study of plaque pathophysiology. <i>European Heart Journal</i> , 2017, 38, 400-412.	1.0	152
330	Segmental comparison between a dedicated bifurcation stent and balloon angioplasty using intravascular ultrasound and three-dimensional quantitative coronary angiography: A subgroup analysis of the Tryton IDE randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, E53-E63.	0.7	4
331	Predictors of long-term outcomes after bypass grafting versus drug-eluting stent implantation for left main or multivessel coronary artery disease. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 177-185.	0.7	7
332	Cherry-Picking Historical Data to Legitimize Contemporary Practice. <i>Journal of the American College of Cardiology</i> , 2017, 69, 404-408.	1.2	3
333	Invasive or non-invasive imaging for detecting high-risk coronary lesions?. <i>Expert Review of Cardiovascular Therapy</i> , 2017, 15, 165-179.	0.6	15
334	Intracoronary optical coherence tomography: Clinical and research applications and intravascular imaging software overview. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 679-689.	0.7	17
335	Outcomes of Coronary Artery Bypass Graft Surgery Versus Drug-Eluting Stents in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2017, 65, 625-630.	1.3	11
336	Single or dual antiplatelet therapy after PCI. <i>Nature Reviews Cardiology</i> , 2017, 14, 294-303.	6.1	35
337	Angiographic assessment of aortic regurgitation by video-densitometry in the setting of TAVI: Echocardiographic and clinical correlates. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 90, 650-659.	0.7	27
338	Coronary bypass surgery versus stenting in multivessel disease involving the proximal left anterior descending coronary artery. <i>Heart</i> , 2017, 103, 428-433.	1.2	19
339	Bioresorbable Scaffold. <i>Circulation Research</i> , 2017, 120, 1341-1352.	2.0	129
340	Quality of Life After Surgery or DES in Patients With 3-Vessel or Left Main Disease. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2039-2050.	1.2	63
341	Clinical Trial Principles and Endpoint Definitions for Paravalvular Leaks in Surgical Prosthesis. <i>Journal of the American College of Cardiology</i> , 2017, 69, 2067-2087.	1.2	88
342	Vasomotor Response to Nitroglycerine Over 5 Years Follow-Up After Everolimus-Eluting Bioresorbable Scaffold Implantation. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 786-795.	1.1	17



#	ARTICLE	IF	CITATIONS
343	Geographical Difference of the Interaction of Sex With Treatment Strategy in Patients With Multivessel Disease and Left Main Disease. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	31
344	Comparison of Outcome of Coronary Artery Bypass Grafting Versus Drug-Eluting Stent Implantation for Non-â€“ST-Elevation Acute Coronary Syndrome. <i>American Journal of Cardiology</i> , 2017, 120, 380-386.	0.7	48
345	Strut protrusion and shape impact on endothelial shear stress: insights from pre-clinical study comparing Mirage and Absorb bioresorbable scaffolds. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 1313-1322.	0.7	23
346	Chronic Total Occlusions. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 889-891.	1.1	0
347	Late thrombotic events after bioresorbable scaffold implantation: a systematic review and meta-analysis of randomized clinical trials. <i>European Heart Journal</i> , 2017, 38, 2559-2566.	1.0	42
348	Prevalence, predictors, and prognostic implications of residual impairment of functional capacity after transcatheter aortic valve implantation. <i>Clinical Research in Cardiology</i> , 2017, 106, 752-759.	1.5	17
349	Accuracy of coronary computed tomography angiography for bioresorbable scaffold luminal investigation: a comparison with optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 431-439.	0.7	11
350	Coronary artery bypass graft surgery versus drug-eluting stent implantation for high-surgical-risk patients with left main or multivessel coronary artery disease. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 51, 943-949.	0.6	2
351	Influence of practice patterns on outcome among countries enrolled in the SYNTAX trial: 5-year results between percutaneous coronary intervention and coronary artery bypass graftingâ€“. <i>European Journal of Cardio-thoracic Surgery</i> , 2017, 52, 445-453.	0.6	18
352	Randomized Comparison of Absorb Bioresorbable Vascular Scaffold and Mirage Microfiber Sirolimus-Eluting Scaffold Using Multimodality Imaging. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1115-1130.	1.1	32
353	Clinical outcomes with percutaneous coronary revascularization vs coronary artery bypass grafting surgery in patients with unprotected left main coronary artery disease: A meta-analysis of 6 randomized trials and 4,686 patients. <i>American Heart Journal</i> , 2017, 190, 54-63.	1.2	78
354	Coronary bioresorbable vascular scaffold radiopaque marker embolization. <i>European Heart Journal</i> , 2017, 38, 1690-1690.	1.0	0
355	IMPACT OF FINAL MINIMAL STENT AREA BY IVUS ON 3-YEAR OUTCOME AFTER PCI OF LEFT MAIN CORONARY ARTERY DISEASE: THE EXCEL TRIAL. <i>Journal of the American College of Cardiology</i> , 2017, 69, 963.	1.2	22
356	Serial Assessment of Tissue Precursors and Progression of Coronary Calcification Analyzed by Fusion of IVUS and OCT. <i>JACC: Cardiovascular Imaging</i> , 2017, 10, 1151-1161.	2.3	31
357	Long-term serial non-invasive multislice computed tomography angiography with functional evaluation after coronary implantation of a bioresorbable everolimus-eluting scaffold: the ABSORB cohort B MSCT substudy. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 870-879.	0.5	13
358	Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. <i>New England Journal of Medicine</i> , 2017, 376, 1321-1331.	13.9	2,249
359	Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. <i>New England Journal of Medicine</i> , 2017, 376, 1824-1834.	13.9	742
360	Efficacy and Safety of the Absorb Everolimus-Eluting Bioresorbable Scaffold for Treatment of Patients with Diabetes Mellitus. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 42-49.	1.1	21

#	ARTICLE	IF	CITATIONS
361	Effect of Technique on Outcomes Following Bioresorbable Vascular Scaffold Implantation. Journal of the American College of Cardiology, 2017, 70, 2863-2874.	1.2	125
362	Quality-of-Life After Everolimus-Eluting Stents or Bypass Surgery for Left-Main Disease. Journal of the American College of Cardiology, 2017, 70, 3113-3122.	1.2	69
363	Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study. European Heart Journal, 2017, 38, 3124-3134.	1.0	244
364	Effect of Post-Dilatation Following Primary PCI With Everolimus-Eluting Bioresorbable Scaffold Versus Everolimus-Eluting Metallic Stent Implantation. JACC: Cardiovascular Interventions, 2017, 10, 1867-1877.	1.1	13
365	Efficacy and Safety of the Absorb Bioresorbable Vascular Scaffold in Females and Males. JACC: Cardiovascular Interventions, 2017, 10, 1881-1890.	1.1	11
366	Serial 5-Year Evaluation of Side Branches Jailed by Bioresorbable Vascular Scaffolds Using 3-Dimensional Optical Coherence Tomography. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	7
367	The Effect of Strut Protrusion on Shear Stress Distribution. JACC: Cardiovascular Interventions, 2017, 10, 1803-1805.	1.1	8
368	2-year outcomes with the Absorb bioresorbable scaffold for treatment of coronary artery disease: a systematic review and meta-analysis of seven randomised trials with an individual patient data substudy. Lancet, The, 2017, 390, 760-772.	6.3	163
369	Improvement in local haemodynamics 5 years after implantation of a coronary bioresorbable scaffold: a pulsatile non-Newtonian shear stress analysis. European Heart Journal Cardiovascular Imaging, 2017, 18, 1294-1294.	0.5	2
370	Comparison of Stenting Versus Bypass Surgery According to the Completeness of Revascularization in Severe Coronary Artery Disease. JACC: Cardiovascular Interventions, 2017, 10, 1415-1424.	1.1	95
371	Impact of Body Mass Index on 5-Year Clinical Outcomes in Patients With ST-Segment Elevation Myocardial Infarction After Everolimus-Eluting or Bare-Metal Stent Implantation. American Journal of Cardiology, 2017, 120, 1460-1466.	0.7	20
372	Shaking and Breaking Calcified Plaque. JACC: Cardiovascular Imaging, 2017, 10, 907-911.	2.3	29
373	Rather Thick, Yet Antithrombogenic. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	5
374	What does the future hold for novel intravascular imaging devices: a focus on morphological and physiological assessment of plaque. Expert Review of Medical Devices, 2017, 14, 985-999.	1.4	5
375	Early invasive strategy should be performed within 72 hours in high-risk patients with non-ST-elevation myocardial infarction. Evidence-Based Medicine, 2017, 22, 227-227.	0.6	1
376	Local Hemodynamic Forces After Stenting. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 2231-2242.	1.1	78
377	Arterial Remodeling After Bioresorbable Scaffolds and Metallic Stents. Journal of the American College of Cardiology, 2017, 70, 60-74.	1.2	51
378	Sealing of calcified plaques after bioresorbable scaffold implantations: a five-year follow up. International Journal of Cardiovascular Imaging, 2017, 33, 451-452.	0.7	3

#	ARTICLE	IF	CITATIONS
379	The effect of strut thickness on shear stress distribution in a preclinical model. <i>International Journal of Cardiovascular Imaging</i> , 2017, 33, 1675-1676.	0.7	3
380	Non-Newtonian pulsatile shear stress assessment: a method to differentiate bioresorbable scaffold platforms. <i>European Heart Journal</i> , 2017, 38, 2570-2570.	1.0	7
381	Percutaneous coronary intervention has similar 5-year survival rates to coronary artery bypass grafting surgery for patients with unprotected left main artery disease. <i>Evidence-Based Medicine</i> , 2017, 22, 151-152.	0.6	0
382	Assessment of the hemodynamic characteristics of Absorb BVS in a porcine coronary artery model. <i>International Journal of Cardiology</i> , 2017, 227, 467-473.	0.8	13
383	Appropriateness of myocardial Revascularization assessed by the SYNTAX score II in a country without cardiac Surgery facilities; PROUST study. <i>International Journal of Cardiology</i> , 2017, 227, 478-484.	0.8	15
384	Cost-effectiveness of percutaneous coronary intervention with cobalt-chromium everolimus eluting stents versus bare metal stents: Results from a patient level meta-analysis of randomized trials. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 994-1002.	0.7	9
385	Impact of Multivessel Coronary Artery Disease With Versus Without Left Main Coronary Artery Disease on Long-Term Mortality After Coronary Bypass Grafting Versus Drug-Eluting Stent Implantation. <i>American Journal of Cardiology</i> , 2017, 119, 225-230.	0.7	11
386	Optimal medical therapy is vital for patients with coronary artery disease and acute coronary syndromes regardless of revascularization strategy. <i>Annals of Translational Medicine</i> , 2017, 5, 140-140.	0.7	10
387	Integration of non-invasive functional assessments with anatomical risk stratification in complex coronary artery disease: the non-invasive functional SYNTAX score. <i>Cardiovascular Diagnosis and Therapy</i> , 2017, 7, 151-158.	0.7	22
388	Intravascular multimodality imaging: feasibility and role in the evaluation of coronary plaque pathology. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 613-620.	0.5	16
389	Tissue characterization with depth-resolved attenuation coefficient and backscatter term in intravascular optical coherence tomography images. <i>Journal of Biomedical Optics</i> , 2017, 22, 1.	1.4	42
390	Possible mechanical causes of scaffold thrombosis: insights from case reports with intracoronary imaging. <i>EuroIntervention</i> , 2017, 12, 1747-1756.	1.4	108
391	The interaction of de novo and pre-existing aortic regurgitation after TAVI: insights from a new quantitative aortographic technique. <i>EuroIntervention</i> , 2017, 13, 60-68.	1.4	15
392	Hierarchical testing of composite endpoints: applying the win ratio to percutaneous coronary intervention versus coronary artery bypass grafting in the SYNTAX trial. <i>EuroIntervention</i> , 2017, 13, 106-114.	1.4	14
393	Is quantitative coronary angiography reliable in assessing the late lumen loss of the everolimus-eluting bioresorbable polylactide scaffold in comparison with the cobalt-chromium metallic stent?. <i>EuroIntervention</i> , 2017, 13, e585-e594.	1.4	6
394	Five-year follow-up of underexpanded and overexpanded bioresorbable scaffolds: self-correction and impact on shear stress. <i>EuroIntervention</i> , 2017, 12, 2158-2159.	1.4	6
395	Difference in haemodynamic microenvironment in vessels scaffolded with Absorb BVS and Mirage BRMS: insights from a preclinical endothelial shear stress study. <i>EuroIntervention</i> , 2017, 13, 1327-1335.	1.4	16
396	First-in-human evaluation of a novel poly-L-lactide based sirolimus-eluting bioresorbable vascular scaffold for the treatment of de novo native coronary artery lesions: MeRes-1 trial. <i>EuroIntervention</i> , 2017, 13, 415-423.	1.4	30

#	ARTICLE	IF	CITATIONS
397	Transcatheter aortic valve implantation for mixed versus pure stenotic aortic valve disease. <i>EuroIntervention</i> , 2017, 13, 1157-1165.	1.4	24
398	A novel synchronised diastolic injection method to reduce contrast volume during aortography for aortic regurgitation assessment: in vitro experiment of a transcatheter heart valve model. <i>EuroIntervention</i> , 2017, 13, 1288-1295.	1.4	14
399	State of the art: coronary angiography. <i>EuroIntervention</i> , 2017, 13, 634-643.	1.4	28
400	State of the art: role of intravascular imaging in the evolution of percutaneous coronary intervention – a 30-year review. <i>EuroIntervention</i> , 2017, 13, 644-653.	1.4	9
401	State of the art: pressure wire and coronary functional assessment. <i>EuroIntervention</i> , 2017, 13, 666-679.	1.4	15
402	Dmax for sizing, PSP-1, PSP-2, PSP-3 or OCT guidance: interventionalist’s jargon or indispensable implantation techniques for short- and long-term outcomes of Absorb BRS?. <i>EuroIntervention</i> , 2017, 12, 2047-2056.	1.4	28
403	What is it to become an octogenarian 40 years after the first angioplasty?. <i>EuroIntervention</i> , 2017, 13, 11-13.	1.4	2
404	Computational simulations in coronary bifurcations: Paving the future of interventional planning. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 1256-1257.	0.7	0
405	Adjudicating paravalvular leaks of transcatheter aortic valves: a critical appraisal. <i>European Heart Journal</i> , 2016, 37, 2627-2644.	1.0	37
406	First generation versus second generation drug-eluting stents for the treatment of bifurcations: 5-year follow-up of the <scp>LEADERS</scp> all-comers randomized trial. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, E248-60.	0.7	44
407	Coronary Artery Bypass Surgery Versus Drug-Eluting Stent Implantation for Left Main or Multivessel Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2481-2489.	1.1	42
408	Incidence, Characteristics, Predictors, and Outcomes of Repeat Revascularization After Percutaneous Coronary Intervention and Coronary Artery Bypass Grafting. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2493-2507.	1.1	85
409	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women Undergoing Complex Percutaneous Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 674-684.	1.1	51
410	Transcatheter Aortic Valve Implantation in Lower-Risk Patients With Aortic Stenosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002944.	1.4	10
411	ABSORB bioresorbable vascular scaffold vs. everolimus-eluting metallic stent in ST-segment elevation myocardial infarction (BVS EXAMINATION study): 2-Year results from a propensity score matched comparison. <i>International Journal of Cardiology</i> , 2016, 214, 483-484.	0.8	20
412	Association of Coronary Stenosis and Plaque Morphology With Fractional Flow Reserve and Outcomes. <i>JAMA Cardiology</i> , 2016, 1, 350.	3.0	108
413	Bioresorbable scaffold – A magic bullet for the treatment of coronary artery disease?. <i>International Journal of Cardiology</i> , 2016, 215, 47-59.	0.8	24
414	The Nidus for Possible Thrombus Formation. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2167-2168.	1.1	30

#	ARTICLE	IF	CITATIONS
415	Plasma cystatin C and neutrophil gelatinase-associated lipocalin in relation to coronary atherosclerosis on intravascular ultrasound and cardiovascular outcome: Impact of kidney function (ATHEROREMO-IVUS study). <i>Atherosclerosis</i> , 2016, 254, 20-27.	0.4	10
416	Individual Long-Term Mortality Prediction Following Either Coronary Stenting or Bypass Surgery in Patients With Multivessel and/or Unprotected Left Main Disease. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1564-1572.	1.1	45
417	Outcomes After Percutaneous Coronary Intervention or Bypass Surgery in Patients With Unprotected Left Main Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 999-1009.	1.2	95
418	The Absorb bioresorbable vascular scaffold for the treatment of coronary artery disease. <i>Expert Opinion on Drug Delivery</i> , 2016, 13, 1489-1499.	2.4	11
419	Computing Methods for Composite Clinical Endpoints in Unprotected Left Main Coronary Artery Revascularization. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2280-2288.	1.1	26
420	Edge Vascular Response After Resorption of the Everolimus-Eluting Bioresorbable Vascular Scaffold – A 5-Year Serial Optical Coherence Tomography Study. <i>Circulation Journal</i> , 2016, 80, 1131-1141.	0.7	16
421	Impact of Implantation Technique and Plaque Morphology on Strut Embedment and Scaffold Expansion of Poly lactide Bioresorbable Scaffold – Insights From ABSORB Japan Trial. <i>Circulation Journal</i> , 2016, 80, 2317-2326.	0.7	28
422	Correlates and Impact of Coronary Artery Calcifications in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1890-1901.	1.1	32
423	Promising, but still a matter of debate. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 378-379.	0.7	1
424	Prognostic Determinants of Coronary Atherosclerosis in Stable Ischemic Heart Disease. <i>Circulation Research</i> , 2016, 119, 317-329.	2.0	40
425	Coronary bifurcations in clinical practice: Tell me what we can do better. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 71-72.	0.7	0
426	Optimisation of percutaneous coronary intervention: indispensables for bioresorbable scaffolds. <i>Expert Review of Cardiovascular Therapy</i> , 2016, 14, 1053-1070.	0.6	2
427	Bioresorbable Vascular Scaffolds for Coronary Revascularization. <i>Circulation</i> , 2016, 134, 168-182.	1.6	108
428	Role of invasive imaging in acute and long-term assessment of bioresorbable scaffold technology. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 38-53.	0.7	13
429	Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. <i>Lancet</i> , The, 2016, 388, 2479-2491.	6.3	451
430	Everolimus-Eluting Stents or Bypass Surgery for Left Main Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2016, 375, 2223-2235.	13.9	843
431	Outcomes of a dedicated stent in coronary bifurcations with large side branches: A subanalysis of the randomized <sc>TRYTON</sc> bifurcation study. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 1231-1241.	0.7	20
432	Acute Gain in Minimal Lumen Area Following Implantation of Everolimus-Eluting ABSORB Biodegradable Vascular Scaffolds or Xience Metallic Stents. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1216-1227.	1.1	18

#	ARTICLE	IF	CITATIONS
433	Long-Term Mortality After Coronary Revascularization in Nondiabetic Patients With Multivessel Disease. <i>Journal of the American College of Cardiology</i> , 2016, 68, 29-36.	1.2	52
434	Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. <i>BMC Cardiovascular Disorders</i> , 2016, 16, 38.	0.7	57
435	Quantitative assessment of the stent/scaffold strut embedment analysis by optical coherence tomography. <i>International Journal of Cardiovascular Imaging</i> , 2016, 32, 871-883.	0.7	35
436	Bioresorption and Vessel Wall Integration of a Fully Bioresorbable Polymeric Everolimus-Eluting Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 838-851.	1.1	31
437	Coronary Artery Bypass Grafting Versus Drug-Eluting Stents Implantation for Previous Myocardial Infarction. <i>American Journal of Cardiology</i> , 2016, 118, 17-22.	0.7	14
438	The Impact of Post-Procedural Asymmetry, Expansion, and Eccentricity of Bioresorbable Everolimus-Eluting Scaffold and Metallic Everolimus-Eluting Stent on Clinical Outcomes in the ABSORB II Trial. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1231-1242.	1.1	80
439	Dual antiplatelet therapy, drug-eluting stents and bioresorbable vascular scaffolds: Evolutionary perspectives. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 909-919.	0.7	5
440	Upstream clopidogrel, prasugrel, or ticagrelor for patients treated with primary angioplasty: Results of an angiographic randomized pilot study. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 1187-1193.	0.7	7
441	1-year outcomes with the Absorb bioresorbable scaffold in patients with coronary artery disease: a patient-level, pooled meta-analysis. <i>Lancet, The</i> , 2016, 387, 1277-1289.	6.3	253
442	Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. <i>European Heart Journal</i> , 2016, 37, 229-240.	1.0	197
443	Vulnerable plaque detection: an unrealistic quest or a feasible objective with a clinical value?. <i>Heart</i> , 2016, 102, 581-589.	1.2	27
444	From drug eluting stents to bioresorbable scaffolds; to new horizons in PCI. <i>Expert Review of Medical Devices</i> , 2016, 13, 271-286.	1.4	29
445	PCSK9 in relation to coronary plaque inflammation: Results of the ATHEROREMO-IVUS study. <i>Atherosclerosis</i> , 2016, 248, 117-122.	0.4	137
446	Balancing idealism with realism to safeguard the welfare of patients: The importance of Heart Team led decision-making in patients with complex coronary artery disease. <i>Indian Heart Journal</i> , 2016, 68, 1-5.	0.2	3
447	A Polylactide Bioresorbable Scaffold Eluting Everolimus for Treatment of Coronary Stenosis. <i>Journal of the American College of Cardiology</i> , 2016, 67, 766-776.	1.2	145
448	Impact of Diabetic Status on Outcomes After Revascularization With Drug-Eluting Stents in Relation to Coronary Artery Disease Complexity. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003255.	1.4	88
449	Risk and timing of recurrent ischemic events among patients with stable ischemic heart disease, non-ST-segment elevation acute coronary syndrome, and ST-segment elevation myocardial infarction. <i>American Heart Journal</i> , 2016, 175, 56-65.	1.2	61
450	Safety and Efficacy of New-Generation Drug-Eluting Stents in Women at High Risk for Atherothrombosis. <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e002995.	1.4	12



#	ARTICLE	IF	CITATIONS
451	Causes of Death Following PCI Versus CABG in Complex CAD. <i>Journal of the American College of Cardiology</i> , 2016, 67, 42-55.	1.2	110
452	Feasibility of 320-row multi-detector computed tomography angiography to assess bioabsorbable everolimus-eluting vascular scaffolds. <i>Cardiovascular Intervention and Therapeutics</i> , 2016, 31, 96-100.	1.2	6
453	Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial. <i>Lancet, The</i> , 2016, 387, 357-366.	6.3	174
454	Noninvasive Prediction of Atherosclerotic Progression: The PROSPECT-MSCT Study. <i>JACC: Cardiovascular Imaging</i> , 2016, 9, 1009-1011.	2.3	27
455	Video densitometric assessment of aortic regurgitation after transcatheter aortic valve implantation: results from the Brazilian TAVI registry. <i>EuroIntervention</i> , 2016, 11, 1409-1418.	1.4	35
456	Observations from the recent FDA Circulatory System Devices Panel meeting on bioresorbable vascular scaffolds. <i>EuroIntervention</i> , 2016, 11, e1569-e1570.	1.4	4
457	One-year clinical outcomes of patients treated with everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a propensity score comparison of patients enrolled in the ABSORB EXTEND and SPIRIT trials. <i>EuroIntervention</i> , 2016, 12, 1255-1262.	1.4	7
458	Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease. <i>EuroIntervention</i> , 2016, 12, e224-e234.	1.4	23
459	Long-term clinical outcomes after percutaneous coronary intervention versus coronary artery bypass grafting for acute coronary syndrome from the DELTA registry: a multicentre registry evaluating percutaneous coronary intervention versus coronary artery bypass grafting for left main treatment. <i>EuroIntervention</i> , 2016, 12, e623-e631.	1.4	17
460	Integrated Biomarker and Imaging Study 3 (IBIS-3) to assess the ability of rosuvastatin to decrease necrotic core in coronary arteries. <i>EuroIntervention</i> , 2016, 12, 734-739.	1.4	28
461	Five-year haemodynamic outcomes of the first-generation SAPIEN balloon-expandable transcatheter heart valve. <i>EuroIntervention</i> , 2016, 12, 775-782.	1.4	21
462	Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial. <i>EuroIntervention</i> , 2016, 12, 861-872.	1.4	61
463	Variability in the measurement of minimum fibrous cap thickness and reproducibility of fibroatheroma classification by optical coherence tomography using manual versus semi-automatic assessment. <i>EuroIntervention</i> , 2016, 12, e987-e997.	1.4	25
464	Is quantitative coronary angiography reliable in assessing the lumen gain after treatment with the everolimus-eluting bioresorbable polylactide scaffold?. <i>EuroIntervention</i> , 2016, 12, e998-e1008.	1.4	16
465	Very late scaffold thrombosis after bioresorbable scaffold implantation: an unexpected new enemy on the horizon or just a false alarm?. <i>EuroIntervention</i> , 2016, 12, 1077-1079.	1.4	3
466	High-sensitivity C-reactive protein predicts 10-year cardiovascular outcome after percutaneous coronary intervention. <i>EuroIntervention</i> , 2016, 12, 345-351.	1.4	24
467	Incidence and predictors of unplanned non-target lesion revascularisation up to three years after drug-eluting stent implantation: insights from a pooled analysis of the RESOLUTE Global Clinical Trial Program. <i>EuroIntervention</i> , 2016, 12, 465-472.	1.4	10
468	Comparative analysis method of permanent metallic stents (XIENCE) and bioresorbable poly-L-lactic (PLLA) scaffolds (Absorb) on optical coherence tomography at baseline and follow-up. <i>EuroIntervention</i> , 2016, 12, 1498-1509.	1.4	51

#	ARTICLE	IF	CITATIONS
469	Four-year experience with the CoreValve transcatheter heart valve. <i>EuroIntervention</i> , 2016, 12, e1039-e1046.	1.4	8
470	Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. <i>EuroIntervention</i> , 2016, 12, 1239-1245.	1.4	92
471	Regular drug-eluting stents versus the dedicated coronary bifurcation sirolimus-eluting BiOSS LIMÂ® stent: the randomised, multicentre, open-label, controlled POLBOS II trial. <i>EuroIntervention</i> , 2016, 12, e1404-e1412.	1.4	27
472	Preclinical assessment of the endothelial shear stress in porcine-based models following implantation of two different bioresorbable scaffolds: effect of scaffold design on the local haemodynamic micro-environment. <i>EuroIntervention</i> , 2016, 12, 1296-1296.	1.4	15
473	Two-year clinical, angiographic, and serial optical coherence tomographic follow-up after implantation of an everolimus-eluting bioresorbable scaffold and an everolimus-eluting metallic stent: insights from the randomised ABSORB Japan trial. <i>EuroIntervention</i> , 2016, 12, 1090-1101.	1.4	127
474	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. <i>BMC Medicine</i> , 2015, 13, 229.	2.3	169
475	Relation Between Bioresorbable Scaffold Sizing Using QCA-Dmax and Clinical Outcomes at 1 Year in 1,232 Patients From 3 Study Cohorts (ABSORB Cohort B, ABSORB EXTEND, and ABSORB II). <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1715-1726.	1.1	50
476	In vitro validation and comparison of different software packages or algorithms for coronary bifurcation analysis using calibrated phantoms: Implications for clinical practice and research of bifurcation stenting. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 554-563.	0.7	23
477	Impact of Mixed Aortic Valve Stenosis on VASC Outcomes and Postprocedural Aortic Regurgitation in Patients Undergoing Transcatheter Aortic Valve Implantation. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 875-885.	0.7	27
478	Comparison between two- and three-dimensional quantitative coronary angiography bifurcation analyses for the assessment of bifurcation lesions: A subanalysis of the TRYTON pivotal IDE coronary bifurcation trial. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, E140-9.	0.7	9
479	Smoking in Relation to Coronary Atherosclerotic Plaque Burden, Volume and Composition on Intravascular Ultrasound. <i>PLoS ONE</i> , 2015, 10, e0141093.	1.1	14
480	The impact of a second arterial graft on 5-year outcomes after coronary artery bypass grafting in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery Trial and Registry. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2015, 150, 597-606.e2.	0.4	18
481	Ex vivo validation of 45 MHz intravascular ultrasound backscatter tissue characterization. <i>European Heart Journal Cardiovascular Imaging</i> , 2015, 16, 1112-1119.	0.5	24
482	Comparison of Zotarolimus- and Everolimus-Eluting Coronary Stents. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002230.	1.4	122
483	Plasma concentrations of molecular lipid species in relation to coronary plaque characteristics and cardiovascular outcome: Results of the ATHEROREMO-IVUS study. <i>Atherosclerosis</i> , 2015, 243, 560-566.	0.4	120
484	Limitation of Infarct Size and No-Reflow by Intracoronary Adenosine Depends Critically on Dose and Duration. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1990-1999.	1.1	37
485	The year in cardiology 2014: coronary intervention. <i>European Heart Journal</i> , 2015, 36, 347-352.	1.0	1
486	A Randomized Trial of a Dedicated Bifurcation Stent Versus Provisional Stenting in the Treatment of Coronary Bifurcation Lesions. <i>Journal of the American College of Cardiology</i> , 2015, 65, 533-543.	1.2	101

#	ARTICLE	IF	CITATIONS
487	Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction. <i>Heart</i> , 2015, 101, 271-278.	1.2	15
488	Long-Term Prognostic Effect of Coronary Atherosclerotic Burden. <i>Circulation: Cardiovascular Imaging</i> , 2015, 8, e002332.	1.3	123
489	Inter-“Core Lab Variability in Analyzing Quantitative Coronary Angiography for Bifurcation Lesions. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 305-314.	1.1	31
490	Long-term forecasting and comparison of mortality in the Evaluation of the Xience Everolimus Eluting Stent vs. Coronary Artery Bypass Surgery for Effectiveness of Left Main Revascularization (EXCEL) trial: prospective validation of the SYNTAX Score II. <i>European Heart Journal</i> , 2015, 36, 1231-1241.	1.0	98
491	Absorb Bioresorbable Vascular Scaffold Versus Everolimus-Eluting Metallic Stent in A-Segment Elevation Myocardial Infarction: 1-Year Results of a Propensity Score Matching Comparison. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 189-197.	1.1	145
492	Differences in baseline characteristics, practice patterns and clinical outcomes in contemporary coronary artery bypass grafting in the United States and Europe: insights from the SYNTAX randomized trial and registry. <i>European Journal of Cardio-thoracic Surgery</i> , 2015, 47, 685-695.	0.6	26
493	Development and Receding of a Coronary Artery Aneurysm After Implantation of a Fully Bioresorbable Scaffold. <i>Circulation</i> , 2015, 131, 764-767.	1.6	12
494	Optimal Medical Therapy Improves Clinical Outcomes in Patients Undergoing Revascularization With Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting. <i>Circulation</i> , 2015, 131, 1269-1277.	1.6	167
495	Association of wall shear stress with long-term vascular healing response following bioresorbable vascular scaffold implantation. <i>International Journal of Cardiology</i> , 2015, 191, 279-283.	0.8	9
496	Snowshoe Versus Ice Skate for Scaffolding of Disrupted Vessel Wall. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 910-913.	1.1	21
497	Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary. <i>European Heart Journal</i> , 2015, 36, 2608-2620.	1.0	187
498	Letter by Iqbal and Serruys Regarding Article, “Postprocedural Aortic Regurgitation in Balloon-Expandable and Self-Expandable Transcatheter Aortic Valve Replacement Procedures: Analysis of Predictors and Impact on Long-Term Mortality: Insights From the FRANCE2 Registry”. <i>Circulation</i> , 2015, 131, e15.	1.6	0
499	Anatomic Characteristics and Clinical Implications of Angiographic Coronary Thrombus. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	11
500	Sex-related Impact on Clinical Outcome of Everolimus-eluting Versus Bare-metal Stents in ST-segment Myocardial Infarction. Insights From the EXAMINATION Trial. <i>Revista Espanola De Cardiologia (English)</i> Tj ETQq0 0 0 BT /Overlock 10 T		
501	Age-Related Effects of Smoking on Coronary Artery Disease Assessed by Gray Scale and Virtual Histology Intravascular Ultrasound. <i>American Journal of Cardiology</i> , 2015, 115, 1056-1062.	0.7	12
502	Validation of the SYNTAX Revascularization Index to Quantify Reasonable Level of Incomplete Revascularization After Percutaneous Coronary Intervention. <i>American Journal of Cardiology</i> , 2015, 116, 174-186.	0.7	29
503	Smoking Is Associated With Adverse Clinical Outcomes in Patients Undergoing Revascularization With PCI or CABG. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1107-1115.	1.2	99
504	Validity of SYNTAX score II for risk stratification of percutaneous coronary interventions: A patient-level pooled analysis of 5433 patients enrolled in contemporary coronary stent trials. <i>International Journal of Cardiology</i> , 2015, 187, 111-115.	0.8	26

#	ARTICLE	IF	CITATIONS
505	Usefulness of Coronary Atheroma Burden to Predict Cardiovascular Events in Patients Presenting With Acute Coronary Syndromes (from the PROSPECT Study). <i>American Journal of Cardiology</i> , 2015, 116, 1672-1677.	0.7	16
506	A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. <i>European Heart Journal</i> , 2015, 36, 3332-3342.	1.0	245
507	Very Late Scaffold Thrombosis. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1901-1914.	1.2	186
508	Usefulness of Beta2-Microglobulin as a Predictor of All-Cause and Nonculprit Lesion-Related Cardiovascular Events in Acute Coronary Syndromes (from the PROSPECT Study). <i>American Journal of Cardiology</i> , 2015, 116, 1034-1040.	0.7	10
509	Predictors of Plaque Rupture Within Nonculprit Fibroatheromas in Patients With Acute Coronary Syndromes. <i>JACC: Cardiovascular Imaging</i> , 2015, 8, 1180-1187.	2.3	28
510	Biomechanical Modeling to Improve Coronary Artery Bifurcation Stenting. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1281-1296.	1.1	84
511	Short- and Long-term Evaluation of Bioresorbable Scaffolds by Optical Coherence Tomography. <i>Interventional Cardiology Clinics</i> , 2015, 4, 333-349.	0.2	0
512	Incidence and Potential Mechanism(s) of Post-Procedural Rise of Cardiac Biomarker in Patients With Coronary Artery Narrowing After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold or Everolimus-Eluting Metallic Stent. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1053-1063.	1.1	36
513	Prospective Assessment of the Diagnostic Accuracy of Instantaneous Wave-Free Ratio to Assess Coronary Stenosis Relevance. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 824-833.	1.1	172
514	Fate of Bioresorbable Vascular Scaffold Metallic Radio-Opaque Markers at the Site of Implantation After Bioresorption. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1130-1132.	1.1	5
515	Local Hemodynamics. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, e149-e150.	1.1	2
516	Reproducibility of intravascular ultrasound radiofrequency data analysis (virtual histology) with a 45-MHz rotational imaging catheter in ex vivo human coronary arteries. <i>Journal of Cardiology</i> , 2015, 65, 134-142.	0.8	9
517	Everolimus-eluting stent versus bare-metal stent in elderly (>75years) versus non-elderly (<75years) patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: Insights from the examination trial. <i>International Journal of Cardiology</i> , 2015, 179, 73-78.	0.8	17
518	Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. <i>European Heart Journal</i> , 2015, 36, 490-500.	1.0	168
519	Prognostic implications of severe coronary calcification in patients undergoing coronary artery bypass surgery: An analysis of the SYNTAX Study. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 199-206.	0.7	32
520	Radial Versus Femoral Access for Angioplasty of ST-segment Elevation Acute Myocardial Infarction With Second-generation Drug-eluting Stents. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2015, 68, 47-53.	0.4	5
521	A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. <i>Lancet, The</i> , 2015, 385, 43-54.	6.3	514
522	Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. <i>EuroIntervention</i> , 2015, 10, 1288-1298.	1.4	34

#	ARTICLE	IF	CITATIONS
523	The ABSORB EXTEND study: preliminary report of the twelve-month clinical outcomes in the first 512 patients enrolled. <i>EuroIntervention</i> , 2015, 10, 1396-1401.	1.4	139
524	Reversal of flow between serial bifurcation lesions: insights from computational fluid dynamic analysis in a population-based phantom model. <i>EuroIntervention</i> , 2015, 11, e1-e3.	1.4	13
525	The need for dedicated bifurcation quantitative coronary angiography (QCA) software algorithms to evaluate bifurcation lesions. <i>EuroIntervention</i> , 2015, 11, V44-V49.	1.4	21
526	Dedicated stents for distal left main stenting. <i>EuroIntervention</i> , 2015, 11, V129-V134.	1.4	9
527	Anatomically correct three-dimensional coronary artery reconstruction using frequency domain optical coherence tomographic and angiographic data: head-to-head comparison with intravascular ultrasound for endothelial shear stress assessment in humans. <i>EuroIntervention</i> , 2015, 11, 407-415.	1.4	40
528	Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data. <i>EuroIntervention</i> , 2015, 11, 746-756.	1.4	42
529	Defective recovery of QT dispersion following transcatheter aortic valve implantation: frequency, predictors and prognosis. <i>Journal of Geriatric Cardiology</i> , 2015, 12, 482-8.	0.2	9
530	Incomplete Stent Apposition Causes High Shear Flow Disturbances and Delay in Neointimal Coverage as a Function of Strut to Wall Detachment Distance. <i>Circulation: Cardiovascular Interventions</i> , 2014, 7, 180-189.	1.4	178
531	Effects of cobalt-chromium everolimus eluting stents or bare metal stent on fatal and non-fatal cardiovascular events: patient level meta-analysis. <i>BMJ, The</i> , 2014, 349, g6427-g6427.	3.0	82
532	Prognostic implications of coronary calcification in patients with obstructive coronary artery disease treated by percutaneous coronary intervention: a patient-level pooled analysis of 7 contemporary stent trials. <i>Heart</i> , 2014, 100, 1158-1164.	1.2	216
533	Serial optical frequency domain imaging in STEMI patients: the follow-up report of TROFI study. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 987-995.	0.5	33
534	Automatic detection of bioresorbable vascular scaffold struts in intravascular optical coherence tomography pullback runs. <i>Biomedical Optics Express</i> , 2014, 5, 3589.	1.5	37
535	Incidence and Imaging Outcomes of Acute Scaffold Disruption and Late Structural Discontinuity After Implantation of the Absorb Everolimus-Eluting Fully Bioresorbable Vascular Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1400-1411.	1.1	108
536	Scaffold and Edge Vascular Response Following Implantation of Everolimus-Eluting Bioresorbable Vascular Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1361-1369.	1.1	23
537	Circulating acute phase proteins in relation to extent and composition of coronary atherosclerosis and cardiovascular outcome: Results from the ATHEROREMO-IVUS study. <i>International Journal of Cardiology</i> , 2014, 177, 847-853.	0.8	16
538	Near-Infrared Spectroscopy Predicts Cardiovascular Outcome in Patients With Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2510-2518.	1.2	162
539	Coronary evaginations are associated with positive vessel remodelling and are nearly absent following implantation of newer-generation drug-eluting stents: an optical coherence tomography and intravascular ultrasound study. <i>European Heart Journal</i> , 2014, 35, 795-807.	1.0	67
540	OCT Assessment of the Long-Term Vascular Healing Response 5 Years After Everolimus-Eluting Bioresorbable Vascular Scaffold. <i>Journal of the American College of Cardiology</i> , 2014, 64, 2343-2356.	1.2	101



#	ARTICLE	IF	CITATIONS
541	Computed tomography angiography for the interventional cardiologist. <i>European Heart Journal Cardiovascular Imaging</i> , 2014, 15, 842-854.	0.5	14
542	Open issues in transcatheter aortic valve implantation. Part 1: patient selection and treatment strategy for transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014, 35, 2627-2638.	1.0	96
543	The impact of everolimus versus other rapamycin derivative-eluting stents on clinical outcomes in patients with coronary artery disease: A meta-analysis of 16 randomized trials. <i>Journal of Cardiology</i> , 2014, 64, 185-193.	0.8	15
544	Short- and Long-Term Implications of a Bioresorbable Vascular Scaffold Implantation on the Local Endothelial Shear Stress Patterns. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 100-101.	1.1	11
545	Comparison of Medtronic CoreValve and Edwards Sapien XT for Transcatheter Aortic Valve Implantation. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 293-295.	1.1	11
546	Long-Term Outcomes of Percutaneous Coronary Interventions or Coronary Artery Bypass Grafting for Left Main Coronary Artery Disease in Octogenarians (from a Drug-Eluting stent for Left main) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5</i>	0.7	64
547	Transapical Versus Transfemoral Aortic Valve Implantation: A Multicenter Collaborative Study. <i>Annals of Thoracic Surgery</i> , 2014, 97, 22-28.	0.7	64
548	Clinical Outcome of Nonculprit Plaque Ruptures in Patients With Acute Coronary Syndrome in the PROSPECT Study. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 397-405.	2.3	47
549	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting for Ostial/Midshaft Lesions in Unprotected Left Main Coronary Artery From the DELTA Registry. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 354-361.	1.1	45
550	Comparison of Percutaneous Coronary Intervention (With Drug-Eluting Stents) Versus Coronary Artery Bypass Grafting in Women With Severe Narrowing of the Left Main Coronary Artery (from the) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 5</i> <i>Cardiology</i> , 2014, 113, 1348-1355.	0.7	14
551	Fusion of optical coherence tomographic and angiographic data for more accurate evaluation of the endothelial shear stress patterns and neointimal distribution after bioresorbable scaffold implantation: comparison with intravascular ultrasound-derived reconstructions. <i>International Journal of Cardiovascular Imaging</i> , 2014, 30, 485-494.	0.7	37
552	Comparison of Newer-Generation Drug-Eluting With Bare-Metal Stents in Patients With Acute ST-Segment Elevation Myocardial Infarction. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 55-63.	1.1	96
553	Non-cardiac surgery in patients with severe aortic stenosis: time to revise the guidelines?: Figure 1. <i>European Heart Journal</i> , 2014, 35, 2346-2348.	1.0	6
554	Effect of the Endothelial Shear Stress Patterns on Neointimal Proliferation Following Drug-Eluting Bioresorbable Vascular Scaffold Implantation. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 315-324.	1.1	108
555	Coronary artery bypass grafting vs. percutaneous coronary intervention for patients with three-vessel disease: final five-year follow-up of the SYNTAX trial. <i>European Heart Journal</i> , 2014, 35, 2821-2830.	1.0	292
556	Impact of Positive and Negative Lesion Site Remodeling on Clinical Outcomes. <i>JACC: Cardiovascular Imaging</i> , 2014, 7, 70-78.	2.3	45
557	Intravascular Ultrasound Guidance to Minimize the Use of Iodine Contrast in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 1287-1293.	1.1	152
558	ORAL immunosuppressive therapy to prevent in-Stent restenosis (RAMSES) cooperation: A patient-level meta-analysis of randomized trials. <i>Atherosclerosis</i> , 2014, 237, 410-417.	0.4	12



#	ARTICLE	IF	CITATIONS
559	Relation of C-Reactive Protein to Coronary Plaque Characteristics on Grayscale, Radiofrequency Intravascular Ultrasound, and Cardiovascular Outcome in Patients With Acute Coronary Syndrome or Stable Angina Pectoris (from the ATHEROREMO-IVUS Study). <i>American Journal of Cardiology</i> , 2014, 114, 1497-1503.	0.7	44
560	Antibodies to periodontal pathogens are associated with coronary plaque remodeling but not with vulnerability or burden. <i>Atherosclerosis</i> , 2014, 237, 84-91.	0.4	46
561	Circulating cytokines in relation to the extent and composition of coronary atherosclerosis: Results from the ATHEROREMO-IVUS study. <i>Atherosclerosis</i> , 2014, 236, 18-24.	0.4	35
562	Prognostic Value of Site SYNTAX Score and Rationale for Combining Anatomic and Clinical Factors in Decision Making. <i>Journal of the American College of Cardiology</i> , 2014, 64, 423-432.	1.2	48
563	Cost-Effectiveness of Percutaneous Coronary Intervention With Drug-Eluting Stents Versus Bypass Surgery for Patients With 3-Vessel or Left Main Coronary Artery Disease. <i>Circulation</i> , 2014, 130, 1146-1157.	1.6	83
564	Open issues in transcatheter aortic valve implantation. Part 2: procedural issues and outcomes after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2014, 35, 2639-2654.	1.0	105
565	Imaging Plaques to Predict and Better Manage Patients With Acute Coronary Events. <i>Circulation Research</i> , 2014, 114, 1904-1917.	2.0	48
566	NOBORI, a biodegradable-polymer biolimus-eluting stent versus durable-polymer drug-eluting stents: A meta-analysis. <i>International Journal of Cardiology</i> , 2014, 174, 151-153.	0.8	2
567	Five-Year Outcomes in Patients With Left Main Disease Treated With Either Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery Trial. <i>Circulation</i> , 2014, 129, 2388-2394.	1.6	440
568	4-Year Clinical Outcomes and Predictors of Repeat Revascularization in Patients Treated With New-Generation Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1617-1625.	1.2	152
569	Predicting 3-Year Mortality After Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 464-470.	1.1	50
570	Serial 2-Dimensional and 3-Dimensional Optical Coherence Tomography Assessment of Overhanging Struts of Drug-Eluting Absorbable Metal Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 575-576.	1.1	3
571	The MI SYNTAX score for risk stratification in patients undergoing primary percutaneous coronary intervention for treatment of acute myocardial infarction: A substudy of the COMFORTABLE AMI trial. <i>International Journal of Cardiology</i> , 2014, 175, 314-322.	0.8	24
572	1-Year Clinical Outcomes of Diabetic Patients Treated With Everolimus-Eluting Bioresorbable Vascular Scaffolds. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 482-493.	1.1	47
573	Principles of Interventions in Acute Structural Heart Disease. , 2014, , 198-200.		0
574	Temporal Evolution of Strut Light Intensity After Implantation of Bioresorbable Polymeric Intracoronary Scaffolds in the ABSORB Cohort B Trial. <i>Circulation Journal</i> , 2014, 78, 1873-1881.	0.7	12
575	Hybrid intravascular imaging: the key for a holistic evaluation of plaque pathology. <i>EuroIntervention</i> , 2014, 10, 296-298.	1.4	4
576	3D optical coherence tomography: new insights into the process of optimal rewiring of side branches during bifurcational stenting. <i>EuroIntervention</i> , 2014, 10, 907-915.	1.4	79

#	ARTICLE	IF	CITATIONS
577	Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: a multi-imaging modality study at 6, 12, 24 and 36 months. <i>EuroIntervention</i> , 2014, 9, 1271-1284.	1.4	212
578	Natural history of optical coherence tomography-detected non-flow-limiting edge dissections following drug-eluting stent implantation. <i>EuroIntervention</i> , 2014, 9, 1085-1094.	1.4	70
579	Fast virtual functional assessment of intermediate coronary lesions using routine angiographic data and blood flow simulation in humans: comparison with pressure wire "fractional flow reserve. <i>EuroIntervention</i> , 2014, 10, 574-583.	1.4	136
580	Bioresorbable scaffolds for coronary artery disease: current status and future prospective. <i>Chinese Medical Journal</i> , 2014, 127, 1141-8.	0.9	1
581	Nine-month angiographic and two-year clinical follow-up of polymer-free sirolimus-eluting stent versus durable-polymer sirolimus-eluting stent for coronary artery disease: the Nano randomized trial. <i>Chinese Medical Journal</i> , 2014, 127, 2153-8.	0.9	14
582	Impact of biodegradable versus durable polymer drug-eluting stents on clinical outcomes in patients with coronary artery disease: a meta-analysis of 15 randomized trials. <i>Chinese Medical Journal</i> , 2014, 127, 2159-66.	0.9	5
583	Three-year outcomes of percutaneous coronary intervention with next-generation zotarolimus-eluting stents for de novo coronary bifurcation lesions. <i>Journal of Invasive Cardiology</i> , 2014, 26, 630-8.	0.4	7
584	New Developments in Hybrid Optical Coherence Tomographic Imaging: Current Status and Potential Implications in Clinical Practice and Research. <i>Current Cardiovascular Imaging Reports</i> , 2013, 6, 411-420.	0.4	1
585	Progress in Treatment by Percutaneous Coronary Intervention: The Stent of the Future. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2013, 66, 483-496.	0.4	34
586	Prediction of 1-Year Mortality in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 737-745.	1.1	54
587	Meta-Analysis of Everolimus-Eluting Versus Paclitaxel-Eluting Stents in Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 914-922.	1.1	181
588	Clinical and Angiographic Characteristics of Patients Likely to Have Vulnerable Plaques. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 1263-1272.	2.3	67
589	Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial. <i>Lancet, The</i> , 2013, 381, 629-638.	6.3	1,490
590	Impact of 3-Dimensional Bifurcation Angle on 5-Year Outcome of Patients After Percutaneous Coronary Intervention for Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1250-1260.	1.1	47
591	Long-Term Clinical Outcomes After Percutaneous Coronary Intervention for Ostial/Mid-Shaft Lesions Versus Distal Bifurcation Lesions in Unprotected Left Main Coronary Artery. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 1242-1249.	1.1	75
592	Incidence and Short-Term Clinical Outcomes of Small Side Branch Occlusion After Implantation of an Everolimus-Eluting Bioresorbable Vascular Scaffold. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 247-257.	1.1	98
593	Five-Year Clinical and Functional Multislice Computed Tomography Angiographic Results After Coronary Implantation of the Fully Resorbable Polymeric Everolimus-Eluting Scaffold in Patients With De Novo Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 999-1009.	1.1	195
594	Paravalvular Leak After Transcatheter Aortic Valve Replacement. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1125-1136.	1.2	374

#	ARTICLE	IF	CITATIONS
595	Hybrid Intravascular Imaging. <i>Journal of the American College of Cardiology</i> , 2013, 61, 1369-1378.	1.2	80
596	Analysis of Stroke Occurring in the SYNTAX Trial Comparing Coronary Artery Bypass Surgery and Percutaneous Coronary Intervention in the Treatment of Complex Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 344-354.	1.1	46
597	Intracoronary Optical Coherence Tomography and Histology of Overlapping Everolimus-Eluting Bioresorbable Vascular Scaffolds in a Porcine Coronary Artery Model. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 523-532.	1.1	84
598	Multislice Computed Tomography Angiography for Noninvasive Assessment of the 18-Month Performance of a Novel Radiolucent Bioresorbable Vascular Scaffolding Device. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1813-1814.	1.2	22
599	Transcatheter Aortic Valve Replacement in Europe. <i>Journal of the American College of Cardiology</i> , 2013, 62, 210-219.	1.2	199
600	Improved Safety and Reduction in Stent Thrombosis Associated With Biodegradable Polymer-Based Biolimus-Eluting Stents Versus Durable Polymer-Based Sirolimus-Eluting Stents in Patients With Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2013, 6, 777-789.	1.1	296
601	The Negative Impact of Incomplete Angiographic Revascularization on Clinical Outcomes and Its Association With Total Occlusions. <i>Journal of the American College of Cardiology</i> , 2013, 61, 282-294.	1.2	257
602	Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. <i>Lancet</i> , 2013, 381, 639-650.	6.3	679
603	Clinical outcomes after zotarolimus and everolimus drug eluting stent implantation in coronary artery bifurcation lesions: insights from the RESOLUTE All Comers Trial. <i>Heart</i> , 2013, 99, 1267-1274.	1.2	36
604	Randomized study to assess the effect of thrombus aspiration on flow area in patients with ST-elevation myocardial infarction: an optical frequency domain imaging study – TROFI trial. <i>European Heart Journal</i> , 2013, 34, 1050-1060.	1.0	103
605	Bioresorbable Drug-Eluting Magnesium-Alloy Scaffold for Treatment of Coronary Artery Disease. <i>International Journal of Molecular Sciences</i> , 2013, 14, 24492-24500.	1.8	109
606	Treatment of complex coronary artery disease in patients with diabetes: 5-year results comparing outcomes of bypass surgery and percutaneous coronary intervention in the SYNTAX trial. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 43, 1006-1013.	0.6	317
607	Quantification of Incomplete Revascularization and its Association With Five-Year Mortality in the Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery (SYNTAX) Trial Validation of the Residual SYNTAX Score. <i>Circulation</i> , 2013, 128, 141-151.	1.6	326
608	Impact of overlapping newer generation drug-eluting stents on clinical and angiographic outcomes: pooled analysis of five trials from the international Global RESOLUTE Program. <i>Heart</i> , 2013, 99, 626-633.	1.2	31
609	Late Cardiac Remodeling After Primary Percutaneous Coronary Intervention. <i>Circulation Journal</i> , 2013, 77, 81-88.	0.7	38
610	Subgroup Analyses in Trial Reports Comparing Percutaneous Coronary Intervention With Coronary Artery Bypass Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2013, 310, 2097.	3.8	13
611	The CABG SYNTAX Score - an angiographic tool to grade the complexity of coronary disease following coronary artery bypass graft surgery: from the SYNTAX Left Main Angiographic (SYNTAX-LE MANS) substudy. <i>EuroIntervention</i> , 2013, 8, 1277-1285.	1.4	71
612	Advanced three-dimensional quantitative coronary angiographic assessment of bifurcation lesions: methodology and phantom validation. <i>EuroIntervention</i> , 2013, 8, 1451-1460.	1.4	36

#	ARTICLE	IF	CITATIONS
613	Emerging technologies: polymer-free phospholipid encapsulated sirolimus nanocarriers for the controlled release of drug from a stent-plus-balloon or a stand-alone balloon catheter. <i>EuroIntervention</i> , 2013, 9, 148-156.	1.4	93
614	In vivo assessment of the three-dimensional haemodynamic micro-environment following drug-eluting bioresorbable vascular scaffold implantation in a human coronary artery: fusion of frequency domain optical coherence tomography and angiography. <i>EuroIntervention</i> , 2013, 9, 890-890.	1.4	17
615	Revisiting: "Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients". <i>EuroIntervention</i> , 2013, 9, 891-892.	1.4	7
616	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. <i>European Heart Journal</i> , 2012, 33, 2403-2418.	1.0	900
617	Updated standardized endpoint definitions for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document (VARC-2). <i>European Journal of Cardio-thoracic Surgery</i> , 2012, 42, S45-S60.	0.6	1,605
618	From metallic cages to transient bioresorbable scaffolds: change in paradigm of coronary revascularization in the upcoming decade?. <i>European Heart Journal</i> , 2012, 33, 16-25.	1.0	269
619	Response to Letter Regarding Article, "Stent Thrombosis with Everolimus-Eluting Stents: Meta-Analysis of Comparative Randomized Controlled Trials". <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, .	1.4	0
620	Incidence and multivariable correlates of long-term mortality in patients treated with surgical or percutaneous revascularization in the Synergy between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery (SYNTAX) trial. <i>European Heart Journal</i> , 2012, 33, 3105-3113.	1.0	119
621	Quantitative Optical Frequency Domain Imaging Assessment of In-Stent Structures in Patients With ST-Segment Elevation Myocardial Infarction. <i>Circulation Journal</i> , 2012, 76, 2822-2831.	0.7	9
622	Everolimus-eluting stent versus bare-metal stent in ST-segment elevation myocardial infarction (EXAMINATION): 1 year results of a randomised controlled trial. <i>Lancet</i> , The, 2012, 380, 1482-1490.	6.3	412
623	Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. <i>Lancet</i> , The, 2012, 380, 1396-1405.	6.3	143
624	Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: Can the scaffold cap the plaque?. <i>Atherosclerosis</i> , 2012, 221, 106-112.	0.4	115
625	Very Late Coronary Stent Thrombosis of a Newer-Generation Everolimus-Eluting Stent Compared With Early-Generation Drug-Eluting Stents. <i>Circulation</i> , 2012, 125, 1110-1121.	1.6	341
626	Combined anatomical and clinical factors for the long-term risk stratification of patients undergoing percutaneous coronary intervention: the Logistic Clinical SYNTAX score. <i>European Heart Journal</i> , 2012, 33, 3098-3104.	1.0	138
627	ABSORB II randomized controlled trial. <i>American Heart Journal</i> , 2012, 164, 654-663.	1.2	113
628	Consensus Standards for Acquisition, Measurement, and Reporting of Intravascular Optical Coherence Tomography Studies. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1058-1072.	1.2	1,530
629	Quantification and Impact of Untreated Coronary Artery Disease After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2012, 59, 2165-2174.	1.2	310
630	A Global Risk Approach to Identify Patients With Left Main or 3-Vessel Disease Who Could Safely and Efficaciously Be Treated With Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 606-617.	1.1	91

#	ARTICLE	IF	CITATIONS
631	Drug-Eluting Stent for Left Main Coronary Artery Disease. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 718-727.	1.1	121
632	Serial 2- and 3-Dimensional Visualization of Side Branch Jailing After Metallic Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2012, 5, 1089-1090.	1.1	6
633	Definitions and Methodology for the Grayscale and Radiofrequency Intravascular Ultrasound and Coronary Angiographic Analyses. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, S1-S9.	2.3	70
634	Natural History of Coronary Atherosclerosis by Multislice Computed Tomography. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, S28-S37.	2.3	119
635	Agreement and reproducibility of grayscale intravascular ultrasound and optical coherence tomography for the analysis of the bioresorbable vascular scaffold. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 890-902.	0.7	29
636	Proximal and distal maximal luminal diameters as a guide to appropriate deployment of the ABSORB everolimus-eluting bioresorbable vascular scaffold. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 880-888.	0.7	38
637	Validity and variability in visual assessment of stenosis severity in phantom bifurcation lesions: A survey in experts during the fifth meeting of the european bifurcation club. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 361-368.	0.7	32
638	Quantitative multi-modality imaging analysis of a fully bioresorbable stent: a head-to-head comparison between QCA, IVUS and OCT. <i>International Journal of Cardiovascular Imaging</i> , 2012, 28, 467-478.	0.7	47
639	Comparison of in vivo eccentricity and symmetry indices between metallic stents and bioresorbable vascular scaffolds: Insights from the ABSORB and SPIRIT trials. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 219-228.	0.7	46
640	High-speed intracoronary optical frequency domain imaging: implications for three-dimensional reconstruction and quantitative analysis. <i>EuroIntervention</i> , 2012, 7, 1216-1226.	1.4	37
641	Angiographic maximal luminal diameter and appropriate deployment of the everolimus-eluting bioresorbable vascular scaffold as assessed by optical coherence tomography: an ABSORB cohort B trial sub-study. <i>EuroIntervention</i> , 2012, 8, 214-224.	1.4	51
642	Non-invasive fractional flow reserve: scientific basis, methods and perspectives. <i>EuroIntervention</i> , 2012, 8, 511-519.	1.4	33
643	Comparison of intravascular ultrasound versus angiography-guided drug-eluting stent implantation: a meta-analysis of one randomised trial and ten observational studies involving 19,619 patients. <i>EuroIntervention</i> , 2012, 8, 855-865.	1.4	163
644	Age- and gender-related changes in plaque composition in patients with acute coronary syndrome: the PROSPECT study. <i>EuroIntervention</i> , 2012, 8, 929-938.	1.4	78
645	Plaque sealing and passivation with a mechanical self-expanding low outward force nitinol vShield device for the treatment of IVUS and OCT-derived thin cap fibroatheromas (TCFAs) in native coronary arteries: report of the pilot study vShield Evaluated at Cardiac hospital in Rotterdam for Investigation and Treatment of TCEA (SECRITT). <i>EuroIntervention</i> , 2012, 8, 945-954.	1.4	42
646	Bioresorbable Scaffold. <i>Circulation</i> , 2011, 123, 779-797.	1.6	385
647	The Impact of Patient and Lesion Complexity on Clinical and Angiographic Outcomes After Revascularization With Zotarolimus- and Everolimus-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2221-2232.	1.2	101
648	Evaluation of the Second Generation of a Bioresorbable Everolimus-Eluting Vascular Scaffold for the Treatment of De Novo Coronary Artery Stenosis. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1578-1588.	1.2	410



#	ARTICLE	IF	CITATIONS
649	Pitfalls in Plaque Characterization by OCT. JACC: Cardiovascular Imaging, 2011, 4, 810-813.	2.3	103
650	NIRS and IVUS for Characterization of Atherosclerosis in Patients Undergoing Coronary Angiography. JACC: Cardiovascular Imaging, 2011, 4, 647-655.	2.3	76
651	Assessment of Coronary Atherosclerosis Progression and Regression at Bifurcations Using Combined IVUS and OCT. JACC: Cardiovascular Imaging, 2011, 4, 774-780.	2.3	40
652	A Prospective Natural-History Study of Coronary Atherosclerosis. New England Journal of Medicine, 2011, 364, 226-235.	13.9	2,721
653	Value of the SYNTAX score in patients treated by primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: The MI SYNTAXscore study. American Heart Journal, 2011, 161, 771-781.	1.2	106
654	Relation between plaque type and dissections at the edges after stent implantation: An optical coherence tomography study. International Journal of Cardiology, 2011, 150, 151-155.	0.8	70
655	Impact of Body Mass Index on the Five-Year Outcome of Patients Having Percutaneous Coronary Interventions With Drug-Eluting Stents. American Journal of Cardiology, 2011, 108, 195-201.	0.7	37
656	Bypass Versus Drug-Eluting Stents at Three Years in SYNTAX Patients With Diabetes Mellitus or Metabolic Syndrome. Annals of Thoracic Surgery, 2011, 92, 2140-2146.	0.7	84
657	Comparison of in vivo acute stent recoil between the bioresorbable everolimus-eluting coronary scaffolds (revision 1.0 and 1.1) and the metallic everolimus-eluting stent. Catheterization and Cardiovascular Interventions, 2011, 78, 3-12.	0.7	134
658	Standardized endpoint definitions for transcatheter aortic valve implantation clinical trials: a consensus report from the Valve Academic Research Consortium. European Heart Journal, 2011, 32, 205-217.	1.0	719
659	Differential Clinical Responses to Everolimus-Eluting and Paclitaxel-Eluting Coronary Stents in Patients With and Without Diabetes Mellitus. Circulation, 2011, 124, 893-900.	1.6	188
660	The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. EuroIntervention, 2011, 6, 928-935.	1.4	19
661	First-in-man evaluation of intravascular optical frequency domain imaging (OFDI) of Terumo: a comparison with intravascular ultrasound and quantitative coronary angiography. EuroIntervention, 2011, 6, 1037-1045.	1.4	99
662	Clinical expert consensus document on standards for acquisition, measurement and reporting of intravascular ultrasound regression/progression studies. EuroIntervention, 2011, 6, 1123-1130.	1.4	137
663	A novel dedicated 3-dimensional quantitative coronary analysis methodology for bifurcation lesions. EuroIntervention, 2011, 7, 629-635.	1.4	26
664	Angiographic outcomes following stenting or coronary artery bypass surgery of the left main coronary artery: fifteen-month outcomes from the synergy between PCI with TAXUS express and cardiac surgery left main angiographic substudy (SYNTAX-LE MANS). EuroIntervention, 2011, 7, 670-679.	1.4	36
665	Rationale and design of the EXAMINATION trial: a randomised comparison between everolimus-eluting stents and cobalt-chromium bare-metal stents in ST-elevation myocardial infarction. EuroIntervention, 2011, 7, 977-984.	1.4	41
666	Virtual Histology Intravascular Ultrasound Analysis of Non-Culprit Attenuated Plaques Detected by Grayscale Intravascular Ultrasound in Patients With Acute Coronary Syndromes—Conflicts of interest: Dr. Mintz is a member of the speakers bureau of, serves as a consultant for, and has received research and grant support from Volcano Corporation, Rancho Cordova, California. Dr. Stone serves as a consultant for Volcano Corporation. Dr. Leon serves as a consultant for Volcano Corporation. Dr. Kubo has received r. American Journal of Cardiology, 2010, 105, 48-53.	0.7	78



#	ARTICLE	IF	CITATIONS
667	The Impact of Body Mass Index on the One Year Outcomes of Patients Treated by Percutaneous Coronary Intervention With Biolimus- and Sirolimus-Eluting Stents (from the LEADERS Trial). <i>American Journal of Cardiology</i> , 2010, 105, 475-479.	0.7	49
668	Impact of Completeness of Revascularization on the Five-Year Outcome in Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Patients (from the ARTS-II Study). <i>American Journal of Cardiology</i> , 2010, 106, 1369-1375.	0.7	76
669	Efficacy of everolimus eluting stent implantation in patients with calcified coronary culprit lesions: Two-year angiographic and three-year clinical results from the SPIRIT II study. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 634-642.	0.7	106
670	Bifurcation lesions: Functional assessment by fractional flow reserve vs. anatomical assessment using conventional and dedicated bifurcation quantitative coronary angiogram. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 76, 817-823.	0.7	17
671	3-Dimensional Optical Coherence Tomography Assessment of Jailed Side Branches by Bioresorbable Vascular Scaffolds. <i>JACC: Cardiovascular Interventions</i> , 2010, 3, 836-844.	1.1	90
672	Effect of Rosiglitazone on Progression of Coronary Atherosclerosis in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease. <i>Circulation</i> , 2010, 121, 1176-1187.	1.6	95
673	Evaluation of the Second Generation of a Bioresorbable Everolimus Drug-Eluting Vascular Scaffold for Treatment of De Novo Coronary Artery Stenosis. <i>Circulation</i> , 2010, 122, 2301-2312.	1.6	312
674	In Vivo 3D Distribution of Lipid-Core Plaque in Human Coronary Artery as Assessed by Fusion of Near Infrared Spectroscopy-Intravascular Ultrasound and Multislice Computed Tomography Scan. <i>Circulation: Cardiovascular Imaging</i> , 2010, 3, e6-7.	1.3	29
675	The fate of bioresorbable struts located at a side branch ostium: serial three-dimensional optical coherence tomography assessment. <i>European Heart Journal</i> , 2010, 31, 2179-2179.	1.0	44
676	5-Year Clinical Outcomes of the ARTS II (Arterial Revascularization Therapies Study II) of the Sirolimus-Eluting Stent in the Treatment of Patients With Multivessel De Novo Coronary Artery Lesions. <i>Journal of the American College of Cardiology</i> , 2010, 55, 1093-1101.	1.2	218
677	Comparison of Zotarolimus-Eluting and Everolimus-Eluting Coronary Stents. <i>New England Journal of Medicine</i> , 2010, 363, 136-146.	13.9	608
678	Crossing of a calcified "balloon uncrossable" coronary chronic total occlusion facilitated by a laser catheter. <i>International Journal of Cardiology</i> , 2010, 145, 251-254.	0.8	27
679	Outcomes in Patients With De Novo Left Main Disease Treated With Either Percutaneous Coronary Intervention Using Paclitaxel-Eluting Stents or Coronary Artery Bypass Graft Treatment in the Synergy Between Percutaneous Coronary Intervention With TAXUS and Cardiac Surgery (SYNTAX) Trial. <i>Circulation</i> , 2010, 121, 2645-2653.	1.6	561
680	Myocardial infarction adjudication in contemporary all-comer stent trials: balancing sensitivity and specificity. <i>EuroIntervention</i> , 2010, 5, 871-874.	1.4	257
681	In vivo evaluation of stent strut distribution patterns in the bioabsorbable everolimus-eluting device: an OCT ad hoc analysis of the revision 1.0 and revision 1.1 stent design in the ABSORB clinical trial. <i>EuroIntervention</i> , 2010, 5, 932-938.	1.4	73
682	Two-Year Clinical, Angiographic, and Intravascular Ultrasound Follow-Up of the XIENCE V Everolimus-Eluting Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions. <i>Circulation: Cardiovascular Interventions</i> , 2009, 2, 339-347.	1.4	109
683	In vivo validation of CAAS QCA-3D coronary reconstruction using fusion of angiography and intravascular ultrasound (ANGUS). <i>Catheterization and Cardiovascular Interventions</i> , 2009, 73, 620-626.	0.7	70
684	Impact of Vessel Size on Angiographic and Clinical Outcomes of Revascularization With Biolimus-Eluting Stent With Biodegradable Polymer and Sirolimus-Eluting Stent With Durable Polymer. <i>JACC: Cardiovascular Interventions</i> , 2009, 2, 861-870.	1.1	48

#	ARTICLE	IF	CITATIONS
685	In Vivo Assessment of High-Risk Coronary Plaques at Bifurcations With Combined Intravascular Ultrasound and Optical Coherence Tomography. <i>JACC: Cardiovascular Imaging</i> , 2009, 2, 473-482.	2.3	112
686	Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2009, 360, 961-972.	13.9	3,634
687	A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. <i>Lancet, The</i> , 2009, 373, 897-910.	6.3	755
688	Assessment of the SYNTAX score in the Syntax study. <i>EuroIntervention</i> , 2009, 5, 50-56.	1.4	480
689	First direct in vivo comparison of two commercially available three-dimensional quantitative coronary angiography systems. <i>Catheterization and Cardiovascular Interventions</i> , 2008, 71, 44-50.	0.7	43
690	Percutaneous Coronary Intervention or Coronary Artery Bypass Graft for Unprotected Left Main Coronary Artery Disease: The Endless Debate. <i>Journal of the American College of Cardiology</i> , 2008, 52, 582-584.	1.2	6
691	Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. <i>Lancet, The</i> , 2008, 372, 1163-1173.	6.3	607
692	Strain distribution over plaques in human coronary arteries relates to shear stress. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2008, 295, H1608-H1614.	1.5	176
693	Feasibility of combined use of intravascular ultrasound radiofrequency data analysis and optical coherence tomography for detecting thin-cap fibroatheroma. <i>European Heart Journal</i> , 2008, 29, 1136-1146.	1.0	235
694	Three-year follow-up of the ARTS-II# " sirolimus-eluting stents for the treatment of patients with multivessel coronary artery disease. <i>EuroIntervention</i> , 2008, 3, 450-459.	1.4	39
695	Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD. <i>EuroIntervention</i> , 2008, 3, 600-609.	1.4	37
696	Taking the "measure" of a profession. <i>EuroIntervention</i> , 2008, 3, 421-421.	1.4	0
697	The challenge of innovation: lost opportunities and new and uncharted futures. <i>EuroIntervention</i> , 2008, 3, 533-533.	1.4	0
698	The influence of shear stress on in-stent restenosis and thrombosis. <i>EuroIntervention</i> , 2008, 4 Suppl C, C27-32.	1.4	11
699	Late Stent Thrombosis. <i>Circulation</i> , 2007, 115, 1433-1439.	1.6	136
700	Clinical End Points in Coronary Stent Trials. <i>Circulation</i> , 2007, 115, 2344-2351.	1.6	4,993
701	Angiographic Stent Thrombosis After Routine Use of Drug-Eluting Stents in ST-Segment Elevation Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2007, 50, 573-583.	1.2	447
702	Two-year clinical outcome after coronary stenting of small vessels using 2.25-mm sirolimus- and paclitaxel-eluting stents: Insight into the RESEARCH and T-SEARCH registries. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 69, 94-103.	0.7	39

#	ARTICLE	IF	CITATIONS
703	The SCAAR registry or the Swedish yo-yo. EuroIntervention, 2007, 3, 297-300.	1.4	12
704	Medicine in Europe: proudly forging our own unique identity. EuroIntervention, 2007, 3, 167-167.	1.4	0
705	At the dawning of interventional cardiology: Andreas Gruntzig, 30 years after. EuroIntervention, 2007, 3, 293-293.	1.4	0
706	A space for dialogue and innovation, for protocols and practicalities. EuroIntervention, 2007, 3, 15.	1.4	0
707	In vivo validation of a novel three-dimensional quantitative coronary angiography system (CardiOp-B): comparison with a conventional two-dimensional system (CAAS II) and with special reference to optical coherence tomography. EuroIntervention, 2007, 3, 100-8.	1.4	27
708	FDA panel, 7 and 8 December 2006 - The impact on our practice and research. EuroIntervention, 2007, 2, 405-7.	1.4	6
709	Coronary-Artery Stents. New England Journal of Medicine, 2006, 354, 483-495.	13.9	646
710	Long-Term Outcomes After Stenting of Bifurcation Lesions With the "Crush" Technique. Journal of the American College of Cardiology, 2006, 47, 1949-1958.	1.2	228
711	Fourth Annual American College of Cardiology International Lecture. Journal of the American College of Cardiology, 2006, 47, 1754-1768.	1.2	19
712	The SYnergy between percutaneous coronary intervention with TAXus and cardiac surgery (SYNTAX) study: Design, rationale, and run-in phase. American Heart Journal, 2006, 151, 1194-1204.	1.2	281
713	Reproducibility of intravascular ultrasound radiofrequency data analysis: implications for the design of longitudinal studies. International Journal of Cardiovascular Imaging, 2006, 22, 621-631.	0.7	59
714	Revisiting late loss and neointimal volumetric measurements in a drug-eluting stent trial: Analysis from the SPIRIT FIRST trial. Catheterization and Cardiovascular Interventions, 2006, 67, 188-197.	0.7	26
715	Multislice Spiral Computed Tomography for the Evaluation of Stent Patency After Left Main Coronary Artery Stenting. Circulation, 2006, 114, 645-653.	1.6	155
716	INTRAVASCULAR ULTRASOUND PALPOGRAPHY: A NEW METHOD FOR THE DETECTION OF THE VULNERABLE PLAQUE. Journal of Mechanics in Medicine and Biology, 2006, 06, 35-38.	0.3	0
717	Introduction and thoughts on the fourth issue of EuroIntervention. EuroIntervention, 2006, 1, 369.	1.4	0
718	Editorial. EuroIntervention, 2006, 2, 13.	1.4	0
719	The future: EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). EuroIntervention, 2006, 2, 143-5.	1.4	0
720	Editorial. EuroIntervention, 2006, 2, 273-5.	1.4	0

#	ARTICLE	IF	CITATIONS
721	A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent: the SPIRIT II trial. <i>EuroIntervention</i> , 2006, 2, 286-94.	1.4	230
722	“Full metal jacket” (stented length 64 mm) using drug-eluting stents for de novo coronary artery lesions. <i>American Heart Journal</i> , 2005, 150, 994-999.	1.2	74
723	Five-Year Outcomes After Coronary Stenting Versus Bypass Surgery for the Treatment of Multivessel Disease. <i>Journal of the American College of Cardiology</i> , 2005, 46, 575-581.	1.2	559
724	The Effect of Variable Dose and Release Kinetics on Neointimal Hyperplasia Using a Novel Paclitaxel-Eluting Stent Platform. <i>Journal of the American College of Cardiology</i> , 2005, 46, 253-260.	1.2	154
725	The history of EuroPCR... and why a new journal?. <i>EuroIntervention</i> , 2005, 1, 4-5.	1.4	2
726	A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. <i>EuroIntervention</i> , 2005, 1, 58-65.	1.4	186
727	Introduction and thoughts on the second issue of <i>EuroIntervention</i> . <i>EuroIntervention</i> , 2005, 1, 121.	1.4	1
728	Arterial Revascularisation Therapies Study Part II - Sirolimus-eluting stents for the treatment of patients with multivessel de novo coronary artery lesions. <i>EuroIntervention</i> , 2005, 1, 147-56.	1.4	79
729	The SYNTAX Score: an angiographic tool grading the complexity of coronary artery disease. <i>EuroIntervention</i> , 2005, 1, 219-27.	1.4	1,349
730	Terminology for high-risk and vulnerable coronary artery plaques. <i>European Heart Journal</i> , 2004, 25, 1077-1082.	1.0	478
731	The percutaneous assessment of regional and acute coronary hot unstable plaques by thermographic evaluation (PARACHUTE) study: a prospective reproducibility and prognostic clinical study using thermography to predict future ischemic cardiac events. <i>International Journal of Cardiovascular Interventions</i> , 2004, 6, 69-75.	0.5	4
732	Retrospective image-based gating of intracoronary ultrasound images for improved quantitative analysis: The Intelligate method. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 61, 84-94.	0.7	81
733	Direct Stenting Versus Direct Stenting Followed by Centered Beta-Radiation With Intravascular Ultrasound-Guided Dosimetry and Long-Term Anti-Platelet Treatment. <i>Journal of the American College of Cardiology</i> , 2004, 44, 528-537.	1.2	31
734	Actinomycin-eluting stent for coronary revascularization. <i>Journal of the American College of Cardiology</i> , 2004, 44, 1363-1367.	1.2	29
735	Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. <i>Lancet</i> , 2004, 364, 1519-1521.	6.3	1,338
736	Usefulness of shear stress pattern in predicting neointima distribution in sirolimus-eluting stents in coronary arteries. <i>American Journal of Cardiology</i> , 2003, 92, 1325-1328.	0.7	80
737	Extension of Increased Atherosclerotic Wall Thickness Into High Shear Stress Regions Is Associated With Loss of Compensatory Remodeling. <i>Circulation</i> , 2003, 108, 17-23.	1.6	170
738	Focal In-Stent Restenosis Near Step-Up. <i>Circulation</i> , 2002, 105, e185-7.	1.6	48

#	ARTICLE	IF	CITATIONS
739	A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary Revascularization. <i>New England Journal of Medicine</i> , 2002, 346, 1773-1780.	13.9	3,791
740	Nonfluoroscopic Endoventricular Electromechanical Three-Dimensional Mapping. <i>Japanese Circulation Journal</i> , 2001, 65, 695-701.	1.0	1
741	Acute and 6-month clinical and angiographic outcome after implantation of the ACS Duet stent for single-vessel coronary artery disease: Final results of the European and U.S. ACS Multi-link Duet Registry. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 54, 25-33.	0.7	1
742	Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries. <i>Circulation</i> , 2001, 103, 192-195.	1.6	763
743	Relationship Between Neointimal Thickness and Shear Stress After Wallstent Implantation in Human Coronary Arteries. <i>Circulation</i> , 2001, 103, 1740-1745.	1.6	303
744	Real-Time Quantification and Display of Skin Radiation During Coronary Angiography and Intervention. <i>Circulation</i> , 2001, 104, 1779-1784.	1.6	88
745	Coronary Stent Implantation in a Septal Perforator Artery. <i>Japanese Circulation Journal</i> , 2000, 64, 802-804.	1.0	6
746	Improved Regional Wall Motion 6 Months After Direct Myocardial Revascularization (DMR) With the NOGA DMR System. <i>Circulation</i> , 2000, 102, E44-5.	1.6	14
747	True 3-Dimensional Reconstruction of Coronary Arteries in Patients by Fusion of Angiography and IVUS (ANGUS) and Its Quantitative Validation. <i>Circulation</i> , 2000, 102, 511-516.	1.6	196
748	Periprocedural quantitative coronary angiography after Palmaz-Schatz stent implantation predicts the restenosis rate at six months. <i>Journal of the American College of Cardiology</i> , 1999, 34, 1067-1074.	1.2	152
749	Simultaneous Morphological and Functional Assessment of a Renal Artery Stent Intervention With Intravascular Ultrasound. <i>Circulation</i> , 1998, 97, 2575-2576.	1.6	24
750	ECG-Gated Three-dimensional Intravascular Ultrasound. <i>Circulation</i> , 1997, 96, 2944-2952.	1.6	160
751	Optimized expansion of the Wallstent compared with the Palmaz-Schatz stent: On-line observations with two- and three-dimensional intracoronary ultrasound after angiographic guidance. <i>American Heart Journal</i> , 1996, 131, 1067-1075.	1.2	48
752	Inter- and intra-observer variability in the qualitative categorization of coronary angiograms. <i>International Journal of Cardiovascular Imaging</i> , 1996, 12, 21-30.	0.2	45
753	Quantification of the minimal luminal cross-sectional area after coronary stenting by two- and three-dimensional intravascular ultrasound versus edge detection and videodensitometry. <i>American Journal of Cardiology</i> , 1996, 78, 520-525.	0.7	62
754	Utilization of translesional hemodynamics: Comparison of pressure and flow methods in stenosis assessment in patients with coronary artery disease. , 1996, 38, 189-201.		29
755	Reduction in Thrombotic Events With Heparin-Coated Palmaz-Schatz Stents in Normal Porcine Coronary Arteries. <i>Circulation</i> , 1996, 93, 423-430.	1.6	158
756	Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries. <i>Circulation</i> , 1996, 94, 1690-1697.	1.6	726

#	ARTICLE	IF	CITATIONS
757	In vivo validation of an experimental adaptive quantitative coronary angiography algorithm to circumvent overestimation of small luminal diameters. <i>Catheterization and Cardiovascular Diagnosis</i> , 1995, 36, 17-24.	0.7	12
758	Who Was Thrombogenic: The Stent or the Doctor?. <i>Circulation</i> , 1995, 91, 1891-1893.	1.6	51
759	Radiological quality of coronary guiding catheters: A quantitative analysis. <i>Catheterization and Cardiovascular Diagnosis</i> , 1994, 33, 55-60.	0.7	20
760	GRACE?Gianturco-Roubin Stent Acute Closure Evaluation: Substrate, Challenges, and Design of a Randomized Trial of Bailout Management. <i>Journal of Interventional Cardiology</i> , 1994, 7, 333-339.	0.5	10
761	Intracoronary Stents: A Review of the Experience with Five Different Devices in Clinical Use. <i>Journal of Interventional Cardiology</i> , 1994, 7, 117-128.	0.5	8
762	A Comparison of Balloon-Expandable-Stent Implantation with Balloon Angioplasty in Patients with Coronary Artery Disease. <i>New England Journal of Medicine</i> , 1994, 331, 489-495.	13.9	4,235
763	Limitations of the zero crossing detector in the analysis of intracoronary doppler: A comparison with fast fourier transform analysis of basal, hyperemic, and transstenotic blood flow velocity measurements in patients with coronary artery disease. <i>Catheterization and Cardiovascular Diagnosis</i> , 1993, 28, 56-64.	0.7	18
764	Intracoronary blood flow velocity and transstenotic pressure gradient using sensor-tip pressure and doppler guidewires: A new technology for the assessment of stenosis severity in the catheterization laboratory. <i>Catheterization and Cardiovascular Diagnosis</i> , 1993, 28, 311-319.	0.7	33
765	Experimental validation of geometric and densitometric coronary measurements on the new generation cardiovascular angiography analysis system (caas ii). <i>Catheterization and Cardiovascular Diagnosis</i> , 1993, 30, 104-114.	0.7	123
766	Endovascular stents: Preliminary clinical results and future developments. <i>Clinical Cardiology</i> , 1993, 16, 369-378.	0.7	35
767	Intravascular Ultrasonic Assessment of Lumen Geometry and Distensibility of the Angiographically Normal Artery: A Correlation with Quantitative Angiography. <i>Echocardiography</i> , 1992, 9, 133-139.	0.3	10
768	Development of a Polymer Endovascular Prosthesis and its Implantation in Porcine Arteries. <i>Journal of Interventional Cardiology</i> , 1992, 5, 175-186.	0.5	39
769	Percutaneous coronary rotational angioplasty: Preliminary clinical and quantitative imaging results. <i>International Journal of Cardiovascular Imaging</i> , 1991, 7, 47-54.	0.2	3
770	Angiographic Follow-up after Placement of a Self-Expanding Coronary-Artery Stent. <i>New England Journal of Medicine</i> , 1991, 324, 13-17.	13.9	688
771	Disappearance of Spontaneous Echographic Contrast after Balloon Mitral Valvuloplasty: An Indicator of Sustained Hemodynamic Improvement. <i>Journal of Interventional Cardiology</i> , 1990, 3, 109-112.	0.5	0
772	Assessment of the "elong sheath" technique for percutaneous aortic balloon valvuloplasty. <i>Catheterization and Cardiovascular Diagnosis</i> , 1990, 19, 129-135.	0.7	1
773	Intravascular High-Resolution Real-Time Cross-Sectional Echocardiography. <i>Echocardiography</i> , 1989, 6, 9-16.	0.3	23
774	Assessment of dimensions and image quality of coronary contrast catheters from cineangiograms. <i>Catheterization and Cardiovascular Diagnosis</i> , 1985, 11, 521-531.	0.7	88



#	ARTICLE	IF	CITATIONS
775	Magnetic Navigation Wire. , 0, , 32-37.		0